var title_f34_31_35312="Vitiligo - elbow";
var content_f34_31_35312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An irregularly shaped hypopigmented patch is present on the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35312=[""].join("\n");
var outline_f34_31_35312=null;
var title_f34_31_35313="Normal sinus CT";
var content_f34_31_35313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of normal paranasal sinuses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This coronal CT image shows normal maxillary and ethmoid sinuses, with the ostio-meatal complexes widely patent bilaterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marilene B Wang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35313=[""].join("\n");
var outline_f34_31_35313=null;
var title_f34_31_35314="Epinastine: Pediatric drug information";
var content_f34_31_35314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinastine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"    see \"Epinastine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/29/8660?source=see_link\">",
"    see \"Epinastine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elestat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiallergic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"      see \"Epinastine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Children &ge;3 years and Adults: Instill 1 drop into each eye twice daily; continue throughout period of exposure, even in the absence of symptoms",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.05% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestat&reg;: 0.05% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Contact lenses should be removed prior to application; may be reinserted after 10 minutes. Do not wear contact lenses if eyes are red.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Keep tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F165373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning sensation, folliculosis, hyperemia, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection (defined as cold symptoms and upper respiratory infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Lacrimation increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epinastine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for the treatment of contact lens irritation; contains the preservative, benzalkonium chloride, which may be absorbed by soft contact lenses; wait at least 10 minutes after instillation before inserting soft contact lenses. Safety and efficacy in children &lt;3 years of age have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist; inhibits release of histamine from the mast cell",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Low systemic absorption following topical application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &lt;10% metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: I.V.: Urine (55%); feces (30%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/29/8660?source=see_link\">",
"      see \"Epinastine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only. Wash hands before using. Remove contact lenses before application (may be reinserted after ten minutes). May cause blurred vision, temporary stinging or burning sensation. Do not wear contact lenses if eyes are red.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12927 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3D38DFFA37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35314=[""].join("\n");
var outline_f34_31_35314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058343\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058338\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165332\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165323\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058346\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058340\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165373\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058337\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299269\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220116\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165329\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165340\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058336\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058348\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058349\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058342\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=related_link\">",
"      Epinastine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/29/8660?source=related_link\">",
"      Epinastine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35315="Calculator: WHO Infant Head Circumference for Age Percentiles (< 24 months)";
var content_f34_31_35315=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"WHOInfantHeadCircForAge_form\" name=\"WHOInfantHeadCircForAge_form\" onkeydown=\"clrResults();\" onkeyup=\"WHOInfantHeadCircForAge_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: WHO Infant Head Circumference for Age Percentiles (&lt; 24 months)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sex",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input checked=\"checked\" name=\"Sex_radio\" onclick=\"WHOInfantHeadCircForAge_fx();\" type=\"radio\" value=\"Female\"/>",
"             Female",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\">",
"            <br/>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input name=\"Sex_radio\" onclick=\"WHOInfantHeadCircForAge_fx();\" type=\"radio\" value=\"Male\"/>",
"             Male",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"WHOInfantHeadCircForAge_fx(); minMaxCheck();\" onchange=\"WHOInfantHeadCircForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"WHOInfantHeadCircForAge_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mo\">",
"              mo",
"             </option>",
"             <option value=\"12|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Head Circumference",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Head_Circumference_param\" onblur=\"WHOInfantHeadCircForAge_fx(); minMaxCheck();\" onchange=\"WHOInfantHeadCircForAge_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Head_Circumference_unit\" onchange=\"WHOInfantHeadCircForAge_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Z Score",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Percentile",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"WHOInfantHeadCircForAge_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option selected=\"selected\">",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Head Circumference for Age Percentile Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &lt; 2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Microcephaly",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &gt;= 2 and &lt; 98:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Normal head circumference",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &gt;= 98:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Macrocephaly",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Microcephaly is a",
"      <b>",
"       Head Circumference",
"      </b>",
"      greater than two standard deviations below the mean.",
"     </li>",
"     <li>",
"      Macrocephaly is a",
"      <b>",
"       Head Circumference",
"      </b>",
"      greater than two standard deviations above the mean.",
"     </li>",
"     <li>",
"      At the extremes (&gt; 98th percentile or &lt; 2nd percentile), small differences in percentiles represent clinically important differences in head circumference. At these extremes, the z-score is a more precise reflection of how far the measurement deviates from the mean, and is a useful tool for tracking changes.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Examples",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"3\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"40%\">",
"      <tr>",
"       <td align=\"center\" bgcolor=\"#cccccc\">",
"        <b>",
"         Z-score",
"        </b>",
"       </td>",
"       <td align=\"center\" bgcolor=\"#cccccc\">",
"        <b>",
"         Percentile equivalent",
"        </b>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        - 3.0",
"       </td>",
"       <td align=\"center\">",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        - 2.0",
"       </td>",
"       <td align=\"center\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        + 2.0",
"       </td>",
"       <td align=\"center\">",
"        97.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        + 3.0",
"       </td>",
"       <td align=\"center\">",
"        99.7",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Girls: Head-circumference-for-age. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Boys: Head-circumference-for-age. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35315=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.WHOInfantHeadCircForAge_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function WHOInfantHeadCircForAge_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.WHOInfantHeadCircForAge_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Head_Circumference_param.value.indexOf(',') >= 0){ Head_Circumference_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Head_Circumference_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Head_Circumference_unit.options[Head_Circumference_unit.selectedIndex].value.split('|');",
"Head_Circumference = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"if(Sex == 1){",
"if(Age >= 0 && Age < 1){L = 1; M = 33.8787; S = 0.03496;};",
"if(Age >= 1 && Age < 2){L = 1; M = 36.5463; S = 0.03210;};",
"if(Age >= 2 && Age < 3){L = 1; M = 38.2521; S = 0.03168;};",
"if(Age >= 3 && Age < 4){L = 1; M = 39.5328; S = 0.03140;};",
"if(Age >= 4 && Age < 5){L = 1; M = 40.5817; S = 0.03119;};",
"if(Age >= 5 && Age < 6){L = 1; M = 41.4590; S = 0.03102;};",
"if(Age >= 6 && Age < 7){L = 1; M = 42.1995; S = 0.03087;};",
"if(Age >= 7 && Age < 8){L = 1; M = 42.8290; S = 0.03075;};",
"if(Age >= 8 && Age < 9){L = 1; M = 43.3671; S = 0.03063;};",
"if(Age >= 9 && Age < 10){L = 1; M = 43.8300; S = 0.03053;};",
"if(Age >= 10 && Age < 11){L = 1; M = 44.2319; S = 0.03044;};",
"if(Age >= 11 && Age < 12){L = 1; M = 44.5844; S = 0.03035;};",
"if(Age >= 12 && Age < 13){L = 1; M = 44.8965; S = 0.03027;};",
"if(Age >= 13 && Age < 14){L = 1; M = 45.1752; S = 0.03019;};",
"if(Age >= 14 && Age < 15){L = 1; M = 45.4265; S = 0.03012;};",
"if(Age >= 15 && Age < 16){L = 1; M = 45.6551; S = 0.03006;};",
"if(Age >= 16 && Age < 17){L = 1; M = 45.8650; S = 0.02999;};",
"if(Age >= 17 && Age < 18){L = 1; M = 46.0598; S = 0.02993;};",
"if(Age >= 18 && Age < 19){L = 1; M = 46.2424; S = 0.02987;};",
"if(Age >= 19 && Age < 20){L = 1; M = 46.4152; S = 0.02982;};",
"if(Age >= 20 && Age < 21){L = 1; M = 46.5801; S = 0.02977;};",
"if(Age >= 21 && Age < 22){L = 1; M = 46.7384; S = 0.02972;};",
"if(Age >= 22 && Age < 23){L = 1; M = 46.8913; S = 0.02967;};",
"if(Age >= 23 && Age < 24){L = 1; M = 47.0391; S = 0.02962;};",
"if(Age >= 24 && Age < 25){L = 1; M = 47.1822; S = 0.02957;};",
"}",
"if (Sex == 2){",
"if(Age >= 0 && Age < 1){L = 1; M = 34.4618; S = 0.03686;};",
"if(Age >= 1 && Age < 2){L = 1; M = 37.2759; S = 0.03133;};",
"if(Age >= 2 && Age < 3){L = 1; M = 39.1285; S = 0.02997;};",
"if(Age >= 3 && Age < 4){L = 1; M = 40.5135; S = 0.02918;};",
"if(Age >= 4 && Age < 5){L = 1; M = 41.6317; S = 0.02868;};",
"if(Age >= 5 && Age < 6){L = 1; M = 42.5576; S = 0.02837;};",
"if(Age >= 6 && Age < 7){L = 1; M = 43.3306; S = 0.02817;};",
"if(Age >= 7 && Age < 8){L = 1; M = 43.9803; S = 0.02804;};",
"if(Age >= 8 && Age < 9){L = 1; M = 44.5300; S = 0.02796;};",
"if(Age >= 9 && Age < 10){L = 1; M = 44.9998; S = 0.02792;};",
"if(Age >= 10 && Age < 11){L = 1; M = 45.4051; S = 0.02790;};",
"if(Age >= 11 && Age < 12){L = 1; M = 45.7573; S = 0.02789;};",
"if(Age >= 12 && Age < 13){L = 1; M = 46.0661; S = 0.02789;};",
"if(Age >= 13 && Age < 14){L = 1; M = 46.3395; S = 0.02789;};",
"if(Age >= 14 && Age < 15){L = 1; M = 46.5844; S = 0.02791;};",
"if(Age >= 15 && Age < 16){L = 1; M = 46.8060; S = 0.02792;};",
"if(Age >= 16 && Age < 17){L = 1; M = 47.0088; S = 0.02795;};",
"if(Age >= 17 && Age < 18){L = 1; M = 47.1962; S = 0.02797;};",
"if(Age >= 18 && Age < 19){L = 1; M = 47.3711; S = 0.02800;};",
"if(Age >= 19 && Age < 20){L = 1; M = 47.5357; S = 0.02803;};",
"if(Age >= 20 && Age < 21){L = 1; M = 47.6919; S = 0.02806;};",
"if(Age >= 21 && Age < 22){L = 1; M = 47.8408; S = 0.02810;};",
"if(Age >= 22 && Age < 23){L = 1; M = 47.9833; S = 0.02813;};",
"if(Age >= 23 && Age < 24){L = 1; M = 48.1201; S = 0.02817;};",
"if(Age >= 24 && Age < 25){L = 1; M = 48.2515; S = 0.02821;};",
"}",
"Z_Score =  (power((Head_Circumference / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Percentile < 2){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Percentile >= 2) && (Percentile < 98)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Percentile >= 98){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantHeadCircForAge_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 23.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 23.99 mo.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Head_Circumference_param.value && Head_Circumference < 20) {",
"Head_Circumference = 0;",
"Head_Circumference_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Head Circumference is 20 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Head_Circumference_param.value && Head_Circumference > 200) {",
"Head_Circumference_param.value = \"\";",
"clrResults();",
"Head_Circumference = 0;",
"doCalc = false;",
"alert(\"The maximum value for Head Circumference is 200 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantHeadCircForAge_form){",
"",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f34_31_35315=null;
var title_f34_31_35316="Pentoxifylline: Pediatric drug information";
var content_f34_31_35316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentoxifylline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"    see \"Pentoxifylline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/2/25636?source=see_link\">",
"    see \"Pentoxifylline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TRENtal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pentoxifylline SR;",
"     </li>",
"     <li>",
"      Trental&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Viscosity Reducer Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"      see \"Pentoxifylline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Minimal information available; one investigation (Furukawa, 1994) found a lower incidence of coronary artery lesions in 22 children (mean age: 2 years) treated for acute Kawasaki disease with versus without pentoxifylline 20 mg/kg/day (given in 3 divided doses); all patients received aspirin and I.V. gamma globulin therapy; a lower dose (10 mg/kg/day) was not effective; higher doses have been used investigationally for the treatment of cystic fibrosis (Aronoff, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 400 mg 3 times/day with meals; decrease to 400 mg twice daily if CNS or GI side effects occur.",
"     <b>",
"      Note:",
"     </b>",
"     Although clinical benefit may be seen within 2-4 weeks, treatment should be continued for at least 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use with caution; monitor for enhanced therapeutic and toxic effects;",
"     <b>",
"      Note:",
"     </b>",
"     Pentoxifylline is not eliminated unchanged in the urine; however, the pharmacologically active metabolite (M-V) is; M-V may accumulate in patients with renal impairment and add to pharmacologic and toxic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Dosage adjustments not listed by manufacturer; adjust dose based on degree of renal impairment (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: 400 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: 400 mg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 400 mg every 24 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Further dosage reduction may be required; Paap (1996) suggests a further reduction to 200 mg once daily but current products (extended or controlled release; unscored) may require adaptation to 400 mg once every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TRENtal&reg;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or antacids to decrease GI upset. Do not crush, break, or chew extended or controlled release tablet, swallow whole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic management of peripheral vascular disease, mainly intermittent claudication (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Has also been studied for use in AIDS patients with increased tumor necrosis factor, cerebrovascular accidents, cerebrovascular diseases, new onset type I diabetes mellitus, diabetic atherosclerosis, diabetic neuropathy, diabetic nephropathy, gangrene, cutaneous polyarteritis nodosa, hemodialysis shunt thrombosis, cerebral malaria, septic shock, sepsis in premature neonates, sickle cell syndromes, vasculitis, Kawasaki disease, Raynaud's syndrome, cystic fibrosis, bone marrow transplant-related toxicities (ie, graft-versus-host disease, veno-occlusive disease, and interstitial pneumonitis), and persistent pulmonary hypertension of the newborn",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pentoxifylline may be confused with tamoxifen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TRENtal&reg; may be confused with Bentyl&reg;, TEGretol&reg;, Trandate&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, angina, anorexia, aplastic anemia, arrhythmia, aseptic meningitis, blurred vision, chest pain, cholecystitis, conjunctivitis, depression, fibrinogen decreased (serum), hallucinations, hepatitis, hypotension, leukemia, leukopenia, liver enzymes increased, pancytopenia, scotoma, seizure, tachycardia, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentoxifylline, any component, or other xanthine derivatives (eg, caffeine, theophylline, theobromine); recent cerebral or retinal hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment, insulin-treated diabetics, chronic occlusive arterial disease of the limbs, recent surgery, or peptic ulcerations",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F208290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentoxifylline may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Pentoxifylline may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Pentoxifylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May enhance the adverse/toxic effect of Pentoxifylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Pentoxifylline may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): Pentoxifylline may enhance the anticoagulant effect of Heparin (Low Molecular Weight).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Pentoxifylline may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Pentoxifylline may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease rate but not extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism of action remains unclear; is thought to reduce blood viscosity and improve blood flow by altering the rheology of red blood cells; inhibits production of tumor necrosis factor-alpha; inhibits neutrophil activation and adhesion; increases tissue oxygen levels in patients with peripheral arterial disease; inhibits platelet aggregation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 2-4 weeks with multiple doses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Pentoxifylline and metabolites distribute into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes first-pass in the liver, dose-related (nonlinear) pharmacokinetics; 2 active metabolites (M-I and M-V);",
"     <b>",
"      Note:",
"     </b>",
"     Plasma concentrations of M-1 and M-V are 5 and 8 times greater, respectively, than pentoxifylline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, apparent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parent drug: 24-48 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolites: 60-96 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites excreted in urine; 0% eliminated unchanged in the urine: 50% to 80% eliminated as M-V metabolite in the urine; 20% as other metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/2/25636?source=see_link\">",
"      see \"Pentoxifylline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit caffeine; if GI or CNS side effects continue, contact physician; while beneficial effects may be seen in 2-4 weeks, continue treatment for at least 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL oral suspension may be made using tablets. Crush ten 400 mg tablets and reduce to a fine powder. Add a small amount of purified water and mix to a uniform paste; mix while adding purified water to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable 91 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 117.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff SC, Quinn FJ, Carpenter LS, et al, &ldquo;Effects of Pentoxifylline on Sputum Neutrophil Elastase and Pulmonary Function in Patients With Cystic Fibrosis: Preliminary Observations,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(6 Pt 1):992-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/7996376/pubmed\" id=\"7996376\" target=\"_blank\">",
"        7996376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berman W Jr, Berman N, Pathak D, et al, &ldquo;Effects of Pentoxifylline (Trental&reg;) on Blood Flow, Viscosity, and Oxygen Transport in Young Adults With Inoperable Cyanotic Congenital Heart Disease,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1994, 15(2):66-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/7997416/pubmed\" id=\"7997416\" target=\"_blank\">",
"        7997416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furukawa S, Matsubara T, Umezawa Y, et al, &ldquo;Pentoxifylline and Intravenous Gamma Globulin Combination Therapy for Acute Kawasaki Disease,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1994, 153(9):663-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/7957426/pubmed\" id=\"7957426\" target=\"_blank\">",
"        7957426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauterbach R, &ldquo;Pentoxifylline Treatment of Persistent Pulmonary Hypertension of Newborn,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1993, 152(5):460. (I.V. use)",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/8319723/pubmed\" id=\"8319723\" target=\"_blank\">",
"        8319723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauterbach R, Pawlik D, Tomaszczyk B, et al, &ldquo;Pentoxifylline Treatment of Sepsis of Premature Infants; Preliminary Clinical Observations,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1994, 153(9):672-4. (I.V. use)",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/ 7957428 /pubmed\" id=\" 7957428 \" target=\"_blank\">",
"        7957428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacDonald MJ, Shahidi NT, Allen DB, et al, &ldquo;Pentoxifylline in the Treatment of Children With New-Onset Type I Diabetes Mellitus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1994, 271(1):27-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/8258882/pubmed\" id=\"8258882\" target=\"_blank\">",
"        8258882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paap CM, Simpson KS, Horton MW, et al, \"Multiple-Dose Pharmacokinetics of Pentoxifylline and Its Metabolites During Renal Insufficiency,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(7-8):724-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/31/35316/abstract-text/8826548/pubmed\" id=\"8826548\" target=\"_blank\">",
"        8826548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12694 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35316=[""].join("\n");
var outline_f34_31_35316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208250\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208251\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054849\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054843\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208229\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208215\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054852\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054851\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208304\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208302\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054842\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208290\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208224\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054858\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208226\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208238\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054841\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054854\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054855\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054848\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806425\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=related_link\">",
"      Pentoxifylline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/2/25636?source=related_link\">",
"      Pentoxifylline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35317="Diabetes mellitus type 1: Insulin treatment";
var content_f34_31_35317=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/31/35317/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35317/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/31/35317/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35317/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/31/35317/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35317/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/31/35317?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes mellitus is a lifelong condition that can be controlled with lifestyle adjustments and medical treatments. Keeping blood sugar levels under control can prevent or minimize complications. Insulin treatment is one component of a diabetes treatment plan for people with type 1 diabetes.",
"    </p>",
"    <p>",
"     Insulin treatment replaces or supplements the body's own insulin, restoring normal or near-normal blood sugar levels. Many different types of insulin treatment can successfully control blood sugar levels; the best option depends upon a variety of individual factors. With a little extra planning, people with diabetes who take insulin can lead a full life and keep their blood sugar under control.",
"    </p>",
"    <p>",
"     Other topics that discuss type 1 diabetes are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"      \"Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STARTING INSULIN",
"     </span>",
"    </p>",
"    <p>",
"     The pancreas produces very little or no insulin at all in people with type 1 diabetes. All patients with type 1 diabetes will eventually require insulin. Insulin must be given as a shot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;When you are first starting insulin, it will take some time to find the right dose. A doctor or nurse will help to adjust your dose over time. It is important to check your blood sugar level several times per day during this time.",
"    </p>",
"    <p>",
"     Insulin needs often change over your lifetime. Changes in weight, what you eat, health conditions (including pregnancy), activity level, and work can affect the amount of insulin needed to control your blood sugar.",
"    </p>",
"    <p>",
"     Many people are able to adjust their own insulin dose, although you will need help from time to time. Most people with type 1 diabetes meet with a doctor or nurse every three to four months; you will review your blood sugar levels and insulin doses at these visits, helping to fine-tune your diabetes control. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Types",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several different types of insulin. These types are classified according to how quickly they begin working and how long the insulin lasts:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Rapid-acting (eg, insulin lispro [Humalog&reg;], insulin aspart [Novolog&reg;], and insulin glulisine [Apidra&reg;])",
"      </li>",
"      <li>",
"       Short-acting (eg, insulin regular)",
"      </li>",
"      <li>",
"       Intermediate-acting (eg, insulin NPH)",
"      </li>",
"      <li>",
"       Long-acting (eg, insulin glargine [Lantus&reg;], insulin detemir [Levemir&reg;])",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Insulin types can be used in combination to achieve around-the-clock blood sugar control.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      INSULIN REGIMENS",
"     </span>",
"    </p>",
"    <p>",
"     There are two general types of insulin treatment plans: intensive insulin treatment and standard (conventional) insulin treatment. In general, intensive insulin therapy is recommended for people with type 1 diabetes. Standard insulin treatment is an older regimen, although it may still be recommended for selected patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Intensive insulin treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Intensive insulin treatment is best for keeping blood sugar in tight control. You will need to take three or more insulin shots per day or use an insulin pump, and you will need to check your blood sugar frequently.",
"    </p>",
"    <p>",
"     Intensive insulin therapy is recommended for most people with type 1 diabetes, starting as soon as possible. However, this regimen will be successful only if you are fully committed to it and you have good understanding of the regimen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Intensive insulin treatment can improve blood sugar control, which can improve how you feel on a daily basis as well as reduce your risk of health complications later in life [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/31/35317/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Drawbacks",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a few drawbacks to intensive insulin treatment:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You will need to coordinate your daily activities, what you eat, how much and when you exercise, and you will need to check your blood sugar frequently (four or more times per day).",
"      </li>",
"      <li>",
"       There is an increased risk of low blood sugar episodes. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"        \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Some people gain weight initially, although exercise can counteract this effect.",
"      </li>",
"      <li>",
"       It is about three times as expensive as standard insulin treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Staying motivated",
"     </span>",
"     &nbsp;&mdash;&nbsp;Intensive treatment can be demanding and some people lose motivation over time. Your doctor or nurse can provide tips and encouragement to help you stay on track. Helpful information and support is also available from the American Diabetes Association (ADA), at 800-342-2383 and at",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      INJECTING INSULIN",
"     </span>",
"    </p>",
"    <p>",
"     Insulin is usually given as a shot into the skin (this is called a subcutaneous injection). The following figure demonstrates the sites where you can inject insulin (",
"     <a class=\"graphic graphic_figure graphicRef80789 \" href=\"mobipreview.htm?9/58/10145\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     You and your parents or partner should learn to draw up and give insulin shots.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Needle and syringe",
"     </span>",
"     &nbsp;&mdash;&nbsp;You will use a needle and syringe to draw up and inject insulin under the skin. The needle must be injected at the correct angle; injecting too deeply could deliver insulin to the muscle, where it is absorbed quickly. Injecting too shallowly deposits insulin in the skin, which is painful and prevents the body from absorbing the insulin.",
"    </p>",
"    <p>",
"     The best angle for insulin injection depends upon your body type, where you are injecting, and the length of your needle. A doctor or nurse can show you the right angle of injection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Drawing up insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many different types of syringes and needles, so it's best to get specific instructions on drawing up insulin from your doctor or nurse. Basic information is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef54094 \" href=\"mobipreview.htm?16/17/16668\">",
"      table 1",
"     </a>",
"     ). If you use an insulin pen, you should follow the instructions for dosing and giving insulin provided by the pen manufacturer and your doctor (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Insulin pen injectors'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Before drawing up insulin, it is important to know the dose and type of insulin needed. If more than one type of insulin is combined in one syringe, the person drawing up the insulin should calculate the total dose before drawing up the insulin. Some people, including children and those with difficulty seeing, may need assistance. Devices to magnify the syringe markings and simplify the drawing up process are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Injection technique",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following is a description of subcutaneous insulin injection.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Choose the site to inject (",
"       <a class=\"graphic graphic_figure graphicRef80789 \" href=\"mobipreview.htm?9/58/10145\">",
"        figure 1",
"       </a>",
"       ). It is not necessary to clean the skin with alcohol unless the skin is dirty.",
"      </li>",
"      <li>",
"       Pinch up a fold of skin and quickly insert the needle at a 90&ordm; angle (or other angle, as described above) (",
"       <a class=\"graphic graphic_figure graphicRef74635 \" href=\"mobipreview.htm?9/33/9749\">",
"        figure 2",
"       </a>",
"       ). Keep the skin pinched to avoid injecting insulin into the muscle.",
"      </li>",
"      <li>",
"       Push the plunger down completely to inject the insulin. Hold the syringe and needle in place for five seconds.",
"      </li>",
"      <li>",
"       Release the skin fold.",
"      </li>",
"      <li>",
"       Remove the needle from the skin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If blood or clear fluid (insulin) is seen at the injection site, apply pressure to the area for five to eight seconds. The area should not be rubbed because this can cause the insulin to be absorbed too quickly.",
"    </p>",
"    <p>",
"     Needles and syringes should only be used once and then thrown away. Used needles and syringes should not be included with regular household trash, but should instead be placed in a puncture-proof container (also known as a sharps container), available from most pharmacies or hospital supply stores.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Injecting through clothing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people wonder about the safety of injecting insulin through their clothing. One small study examined the risks and benefits of this technique, and found that blood sugar control did not differ between the group that injected insulin through a single layer of clothing and those that injected directly into the skin [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/31/35317/abstract/2\">",
"      2",
"     </a>",
"     ]. There were no reports of infections in either group, although a few people who injected through clothing reported blood stains on their clothing or bruises on the skin. If you are interested in using this technique, speak with your healthcare provider before trying it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Insulin pen injectors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insulin pen injectors may be more convenient to carry and use when away from home. Most are approximately the size of a large writing pen, and contain a disposable insulin cartridge and needle. Some types of insulin and some insulin mixtures are not available in cartridges, meaning that pens may not be an option for everyone.",
"    </p>",
"    <p>",
"     Pens are especially useful for accurately injecting very small doses of insulin, and may be helpful for people with impaired vision. Pens are generally more expensive than traditional syringes and needles. A number of insulin pens are available, and the specific instructions for each type should be obtained from the manufacturer or a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Inhaled insulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007. Other inhaled insulin preparations are in clinical trials but are not currently available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Insulin pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insulin can be continuously administered by insulin pump, a process called continuous subcutaneous insulin infusion. An insulin pump may be recommended if you are willing to closely monitor your blood sugar levels, amount and type of food eaten, and other factors.",
"    </p>",
"    <p>",
"     The pump is worn externally (in a pocket or on the belt) and is attached to the body with long, thin, flexible plastic tubing that has a needle or soft cannula (thin plastic tube). The cannula or needle is inserted and then left in place beneath the skin. You change the needle or cannula and tubing every 48 to 72 hours. The pump stores rapid acting insulin in a cartridge.",
"    </p>",
"    <p>",
"     The pump is programmed to give a small dose of insulin continuously through the day and night. At meal times, you must program the pump to give an additional dose of insulin, based upon your blood sugar level and amount of food you plan to eat. The pump can be taken off for up to one hour without impacting blood sugar control; if it is taken off for longer periods of time, insulin injections may be needed to control the blood sugar.",
"    </p>",
"    <p>",
"     The insulin pump has advantages and disadvantages; it may be helpful to talk with a person who uses a pump before deciding to try it. Most pump manufacturers have a list of people willing to speak with prospective pump users. It may also be possible to use a trial pump for a few days before committing to it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Advantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insulin pumps have the advantage of flexible timing of meals and other day-to-day events, similar to intensive treatment regimens that combine very-rapid acting and long-acting insulins. This can be of great benefit for children or adults whose schedule varies from one day to the next. People who use an insulin pump do not require multiple daily injections; most patients who use the pump change their injection site every 48 to 72 hours.",
"    </p>",
"    <p>",
"     The other major advantage of an insulin pump is that there is less variation in the amount of insulin absorbed compared with when insulin is given with a needle and syringe. This can help reduce day-to-day variations in blood sugar levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Disadvantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cost of an insulin pump and supplies is greater than the cost of insulin syringes and needles, although most insurance carriers cover some portion of the expenses. Some patients develop pump-associated problems, including skin infection at the injection site or pump malfunction.",
"    </p>",
"    <p>",
"     You must take care to monitor your blood sugar levels carefully; stopping insulin, even for a short time, can lead to a significant increase in blood sugar. Some people find the pump awkward, unpleasant, or embarrassing. However, you can disconnect the pump for brief periods, if desired.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      FACTORS AFFECTING INSULIN ACTION",
"     </span>",
"    </p>",
"    <p>",
"     Several factors can affect how insulin is absorbed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Dose of insulin injected",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dose of insulin injected affects the rate at which your body absorbs it. For example, larger doses of insulin may be absorbed more slowly than a small dose. With larger doses of insulin, the insulin may peak later or last longer than with small doses. This could mean that your blood sugar level is higher than expected within a few hours after eating, but then becomes low.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Injection technique",
"     </span>",
"     &nbsp;&mdash;&nbsp;The angle and depth of an insulin injection are important, as mentioned above (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Needle and syringe'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Site of injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Clinicians usually recommend changing your injection site to minimize tissue irritation. However, it is important to keep in mind that insulin is absorbed at different rates in different areas of the body. Insulin is absorbed fastest from the abdominal area, slowest from the leg and buttock, and at an intermediate rate from the arm. This may vary with the amount of fat under the skin; the more fat, the more slowly insulin is absorbed (",
"     <a class=\"graphic graphic_figure graphicRef80789 \" href=\"mobipreview.htm?9/58/10145\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Because of variations in absorption, it is reasonable to use the same general area for injections at a particular time of the day. Pre-meal insulin injections are absorbed fastest from the abdominal area, allowing for optimal coverage of carbohydrates consumed in a meal. Injection into the thigh or buttock may be best for the evening dose because the insulin will be absorbed more slowly during the night.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Subcutaneous blood flow",
"     </span>",
"     &nbsp;&mdash;&nbsp;Any factors that alter the rate of blood flow to the body's tissues will alter insulin absorption. Smoking actually decreases blood flow to the tissues and decreases absorption of injected insulin. In contrast, factors that increase the skin temperature (such as exercise, saunas, hot baths, and massage of the injection site) will increase insulin absorption.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Time since opening the bottle",
"     </span>",
"     &nbsp;&mdash;&nbsp;While most insulin remains potent and effective for up to a month after the bottle has been opened (if kept in the refrigerator between injections) the potency for intermediate or long-acting insulin begins to decrease after 30 days. This can be a problem for people who require very small doses of insulin, for whom a bottle might last two months or more. It is advisable to open a new bottle at least every 30 days, even if there is insulin left in the old bottle.",
"    </p>",
"    <p>",
"     For rapid-acting insulin used in pen injectors, it is acceptable to keep the pen injector unrefrigerated (in a bag or jacket pocket) for up to 14 days, provided that the pen is not exposed to very warm or cold conditions. However, after 14 days, a new insulin cartridge or pen should be used, even if there is insulin left in the old cartridge.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Individual factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The same dose of the same type of insulin may have different effects in different people with diabetes. Some trial and error is usually necessary to find the ideal type(s) and dose of insulin and schedule for each person.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      SPECIAL SITUATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Several special situations can complicate insulin treatment. With advance planning and close monitoring, these situations are less likely to cause serious difficulties. A healthcare provider can help to handle these situations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Eating out",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eating out can be challenging since ingredients used, calorie and fat content, and portion sizes are usually different from meals prepared at home. You can estimate the carbohydrate content of meals to calculate insulin dose; nutrition information is often available from restaurants or a hand-held reference book.",
"    </p>",
"    <p>",
"     Low or high blood sugar levels can occur more easily in situations where new or different foods are eaten; a fast-acting source of carbohydrates (eg, candy, glucose tablets) and a blood glucose monitor should be kept on hand at all times. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"      \"Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who have surgery may be instructed not to eat for 8 to 12 hours before their procedure. A healthcare provider can help to determine the dose and timing of insulin before and after the procedure, especially if you will be unable to eat a normal diet afterwards.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mild infections, such as a cold, sore throat, or urinary tract infection, can cause blood sugar levels to rise and can even lead to diabetic ketoacidosis. In this situation, frequent telephone contact with a healthcare provider, careful blood sugar monitoring, and increasing the insulin dose are often recommended. Patients with nausea or vomiting may require medication to control their symptoms and avoid dehydration and ketoacidosis. If dehydration occurs, treatment with intravenous (IV) fluids may be necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      Travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Managing blood sugar levels and insulin treatment while traveling can be difficult, especially when traveling across multiple time zones. In addition, activity levels and diet are often different while traveling, making careful blood sugar monitoring essential. Speak with your healthcare provider before traveling to develop a treatment plan. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link&amp;anchor=H21#H21\">",
"      \"Patient information: General travel advice (Beyond the Basics)\", section on 'Traveling with medical conditions'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804507589\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13090785\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/47/6899?source=see_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=see_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=see_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=see_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=see_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=see_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13090962\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H33\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=see_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15353?source=see_link\">",
"      Inhaled insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27641?source=see_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7162?source=see_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29688?source=see_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18135?source=see_link\">",
"      The adult patient with brittle diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Diabetes Associates",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.ca\">",
"      www.diabetes.ca",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Juvenile Diabetes Research Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.jdrf.org/\">",
"      www.jdrf.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/diabetes\">",
"      www.cdc.gov/diabetes",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/31/35317/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/31/35317?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35317/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35317/abstract/2\">",
"      Fleming DR, Jacober SJ, Vandenberg MA, et al. The safety of injecting insulin through clothing. Diabetes Care 1997; 20:244.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_31_35317=[""].join("\n");
var outline_f34_31_35317=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STARTING INSULIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           INSULIN REGIMENS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           INJECTING INSULIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           FACTORS AFFECTING INSULIN ACTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           SPECIAL SITUATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/58/10145\" title=\"figure 1\">",
"           Insulin injection PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/33/9749\" title=\"figure 2\">",
"           Insulin injection sites PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/17/16668\" title=\"table 1\">",
"           Drawing up insulin PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35318="Atrial pacemaker tutorial";
var content_f34_31_35318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial  pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 125px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A single pacemaker spike (marked by red lines) is followed by a P wave, normal PR interval, and normal QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35318=[""].join("\n");
var outline_f34_31_35318=null;
var title_f34_31_35319="Protocols for stress echocardiography";
var content_f34_31_35319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protocols for stress echocardiography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35319/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/31/35319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography enables evaluation of cardiac function at rest and during dynamic exercise or pharmacologic stress. Exercise two-dimensional imaging is used primarily to detect the presence and extent of coronary artery disease by provoking regional ischemia; addition of exercise Doppler permits evaluation of valvular function, pulmonary artery pressure, and global ventricular systolic and diastolic function.",
"   </p>",
"   <p>",
"    The two major types of stress echocardiography are exercise (treadmill or bicycle) and pharmacologic (predominantly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) stress. In 2007 the American Society of Echocardiography (ASE) published recommendations for the performance, interpretation, and application of stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2008 the European Association of Echocardiography (EAE) published an expert consensus statement on stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/2\">",
"     2",
"    </a>",
"    ]. Echocardiographic contrast agents may be useful to enhance wall motion analysis when image acquisition is suboptimal or technically difficult. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protocols for stress echocardiography will be discussed here. Indications, technique, and safety of stress echocardiography, as well as the advantages and disadvantages of stress echocardiography as compared to other stress modalities, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41048?source=see_link\">",
"     \"Stress echocardiography: Indications, imaging techniques and safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Stress test options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXERCISE TWO-DIMENSIONAL ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise stress is generally preferred to pharmacologic stress for patients who can perform an exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ]. One exception to this recommendation is the evaluation of preoperative risk and myocardial viability for which most of the data have been derived with pharmacologic (largely",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom-limited exercise according to a standard protocol with either treadmill or bicycle (upright or supine) exercise is recommended. Since suboptimal stress is a primary cause of false-negative studies, an adequate level of stress (generally defined as achievement of at least 85 percent of the patient's age-predicted maximal heart rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rate-pressure product of at least 20,000) is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 ASE guidelines note that if evaluation of wall motion is the only purpose of the study, then treadmill exercise is usually used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ]. If stress Doppler information is desired, bicycle exercise offers the advantage of allowing Doppler as well as wall motion evaluation during each stage of exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Treadmill",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise echocardiography is most commonly performed using a treadmill protocol while acquiring echocardiographic images prior to and immediately after the peak treadmill exercise is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This method requires that the patient move from the treadmill into a recumbent position for imaging within a few seconds so that a complete set of images can be obtained within 60 seconds after peak exercise prior to the heart rate, decreasing toward baseline during recovery. Due to tachypnea and tachycardia that develop at peak exercise, the heart is frequently visible for only one or two beats at end expiration.",
"   </p>",
"   <p>",
"    Early image acquisition is necessary since ischemia induced wall motion abnormalities may resolve rapidly as the heart rate slows, causing a decrease in the sensitivity of the test, especially for single vessel disease. Failure to achieve or exceed target heart rate also decreases sensitivity. Motivation and",
"    <span class=\"nowrap\">",
"     experience/competence",
"    </span>",
"    of a laboratory's",
"    <span class=\"nowrap\">",
"     clinician/sonographer",
"    </span>",
"    team influence the reliability of this test. Reports suggest that imaging during rather than after treadmill stress may be feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and yield greater sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/6\">",
"     6",
"    </a>",
"    ], although this approach has not be widely adopted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bicycle ergometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some laboratories perform stress echocardiography using supine or upright bicycle ergometry. The peak heart rate and achieved double product (the product of peak heart rate and peak systolic blood pressure) are usually lower and the achieved blood pressure is higher after a bicycle protocol than a treadmill test. Published data comparing the two techniques show that they have similar sensitivities for detecting coronary disease.",
"   </p>",
"   <p>",
"    A typical supine bicycle protocol increases the workload by 25 W every three minutes until an endpoint is achieved. In this protocol, an exercise duration of 10 to 15 minutes is typical for a healthy adult without endurance training. The protocol can be modified during image acquisition to allow complete data collection without increasing the workload once maximum capacity is reached.",
"   </p>",
"   <p>",
"    A major advantage of bicycle ergometry is that it allows continuous monitoring of wall motion during exercise (eg, at initial workload of 25 W and at peak exercise). Though technically more demanding, such monitoring may yield higher quality images than acquired with only post stress images. More importantly, imaging throughout the study (so that rest, intermediate, peak and recovery images are obtained) may permit detection of the onset and disappearance of transient wall motion abnormalities and improve sensitivity of detection of coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/8\">",
"     8",
"    </a>",
"    ]. An additional advantage of continuous imaging is that during low level stress, an improvement in a dysfunctional wall is equivalent to improvement with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ; therefore, a segment that improves during low level exercise has a high likelihood of viability. If segmental wall motion deteriorates beyond its resting level of dysfunction at peak stress, then the affected segment has a high likelihood of being supplied by stenosed coronary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC STRESS ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic stress is employed in patients who are unable to perform exercise testing. In addition, it may be preferred to exercise testing for preoperative risk and myocardial viability assessment since the majority of data validating stress echocardiography for this indication involved pharmacologic (largely",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) stress. It is also considered the stress method of choice for detecting the type of coronary disease (ie, cardiac allograft vasculopathy) that uniquely develops in transplanted hearts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic stress testing most commonly involves the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    as needed to achieve the target heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. For standard pharmacologic stress echocardiography for assessment of regional wall motion, dobutamine is preferred to vasodilator stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dobutamine stress echocardiography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress test components (as described by the 2007 ASE guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ]) are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graded",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      infusion in five three-minute stages starting at 5",
"      <span class=\"nowrap\">",
"       mcg/kg/minute,",
"      </span>",
"      followed by 10, 20, 30, and 40",
"      <span class=\"nowrap\">",
"       mcg/kg/minute.",
"      </span>",
"      An initial dose of 2.5",
"      <span class=\"nowrap\">",
"       mcg/kg/minute",
"      </span>",
"      is sometimes employed in tests evaluating viability. Low-dose stages facilitate recognition of viability and ischemia in segments with abnormal function at rest, even when viability evaluation is not the main aim of the test.",
"     </li>",
"     <li>",
"      End points are achievement of target heart rate (defined as 85 percent of the age-predicted maximum heart rate), new or worsening wall-motion abnormalities of moderate degree, significant arrhythmias, hypotension, severe hypertension, and intolerable symptoms.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      , in divided doses of 0.5 mg to a total of 2.0 mg, should be administered as needed to achieve target heart rate. Atropine increases the sensitivity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography in patients receiving beta-blockers and in those with single-vessel disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. Some laboratories also use a sustained isometric hand grip or a low level dynamic foot exercise (with or without atropine) in the late stages of the dobutamine protocol as a supplemental maneuver to achieve peak heart rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of recovery wall motion abnormalities after administration of beta blocker (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    1 to 5 mg) after peak stress imaging may increase test sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations from the standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    protocol have been proposed. Some laboratories use a sixth dose of 50",
"    <span class=\"nowrap\">",
"     mcg/Kg/min,",
"    </span>",
"    and others, based on pharmacokinetic data, extend the 40 mcg infusion to 5 minutes. Some omit the first low dose stage when no viability evaluation is sought. If viability testing is performed, it is generally not necessary to administer doses higher than 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/Kg/min.",
"    </span>",
"    Accelerated dobutamine protocols have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress safety is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41048?source=see_link\">",
"     \"Stress echocardiography: Indications, imaging techniques and safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;During",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress, beta blocker therapy attenuates evidence of myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The effect of beta blockers on the heart rate response to dobutamine can usually be overcome by the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The predictive value of pharmacologic stress echocardiography is also influenced by therapy with calcium channel blockers or nitrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/21\">",
"     21",
"    </a>",
"    ]. In the presence of such antiischemic therapy, a positive test carries a more serious prognosis, while a negative test is less benign.",
"   </p>",
"   <p>",
"    As a result, it may be appropriate to withhold antiischemic therapy for at least 12 hours prior to a stress study, unless the risk of an unstable ischemic syndrome or uncontrolled hypertension is thought to be high. However, in a patient with known coronary artery disease, continuation of medications may be preferred if the clinical objectives of the test include assessing the adequacy of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vasodilator stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    , administered at up to 0.84",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 10 minutes (about double the dose used for radionuclide scintigraphy), is a popular pharmacologic regimen for stress echocardiography in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Adenosine is a shorter acting agent employed for myocardial perfusion contrast echocardiography, and to a lesser extent to detect stress induced changes in wall motion, but this method has not been in wide clinical use. Vasodilator stress may be better suited for perfusion than wall motion analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither adenosine nor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress echocardiography is widely used in the United States, and neither approach was recommended for the diagnosis or risk stratification of CHD by the 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    Task Force on chronic stable angina. In the 2007 American Society of Echocardiography (ASE) stress echocardiography guidelines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    is preferred to vasodilators for assessment of regional wall motion.",
"   </p>",
"   <p>",
"    One potentially useful strategy is the administration of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    first and, if negative, followed immediately with a standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    protocol; this strategy may yield a more sensitive test than either dipyridamole or dobutamine alone in detecting myocardial viability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10049168\">",
"    <span class=\"h1\">",
"     OTHER STRESS METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other stress echocardiography methods have been investigated and were discussed in the 2007 ASE guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia induced from a pacemaker is an alternative to pharmacologic stress in patients who are not able to exercise. Stress testing using a permanent pacemaker is achieved by increasing the pacing rate until the target heart rate is achieved; this stress method can be used by itself or combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . Another option is temporary transesophageal pacing using an esophageal lead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/27\">",
"     27",
"    </a>",
"    ]. The pacing protocol consists of three 2-minute stages starting with a first stage with paced rate at",
"    <span class=\"nowrap\">",
"     10/min",
"    </span>",
"    above the patient's baseline heart rate. The paced rate is then increased to 85 percent (prepeak) and 100 percent (peak) target heart rate. Wenckebach second-degree heart block may occur which can be abolished with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . The test has been reported to be well-tolerated, with accuracy comparable to dobutamine stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/28\">",
"     28",
"    </a>",
"    ] or nuclear stress imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Handgrip exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Handgrip may be used alone or as an adjunct to exercise or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. During the last stage of exercise or dobutamine infusion and 30 seconds before acquiring the peak exercise images, patients are asked to exert a sustained grip on a tennis ball to about 30 percent of maximum strength. The hand grip response reliably raises blood pressure at least 10 mmHg and usually also increases heart rate; superimposed on the maximum achieved levels, this augmentation results in an \"bonus\" increment in rate pressure product. In patients with severe ischemia, handgrip alone may induce wall motion abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROTOCOLS FOR SPECIFIC INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 ASE stress echocardiography guidelines recommended the following indication-specific protocols for data acquisition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dyspnea of possible cardiac origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram at rest can provide data on atrial and ventricular size, ventricular hypertrophy, valve disease, regional and global systolic ventricular function, ventricular relaxation and estimates of filling pressures and pulmonary artery systolic pressure. When data at rest are not sufficient to make a diagnosis, supine bike exercise is recommended as it allows Doppler recordings during exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"     1",
"    </a>",
"    ]. Evaluation should include mitral inflow velocities at rest, during exercise and in recovery (when heart rate has slowed sufficiently so that E and A velocities are no longer fused) as well as tissue Doppler recordings of mitral annulus early diastolic velocity (E'). The ratio of",
"    <span class=\"nowrap\">",
"     E/E'",
"    </span>",
"    can be used to estimate left ventricular filling pressures at rest and with exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=see_link&amp;anchor=H5#H5\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Tissue Doppler imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of pulmonary hypertension includes rest and post-exercise pulmonary artery systolic pressures as well as right and left ventricular volumes and function. Some patients with normal pulmonary artery pressures at rest have marked increases with exercise; the significance of this finding has not been defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, the normal ranges for Doppler estimates of pulmonary artery pressure at rest and with supine bike exercise are higher in highly trained athletes and subjects in the seventh decade (as high as 60 mmHg with exercise) compared with healthy young controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mitral stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis evaluation includes measurement of transmitral pressure gradients and tricuspid regurgitation velocities at rest and with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. In sedentary patients with exercise-induced dyspnea and increase in mean transmitral pressure gradient to greater than 15 mm Hg and pulmonary artery systolic pressure to greater than 60 mmHg identifies patients who may benefit from valvotomy if anatomy is suitable and mitral regurgitation is no more than mild. On the other hand, if marked increases in pulmonary artery systolic pressure are accompanied by minimal change in mitral gradient, a pulmonary cause should be sought.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress may be used in patients unable to exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical management and indications for intervention in mitral stenosis\", section on 'Indications for intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of mitral regurgitation severity and pulmonary artery pressure during rest and exercise may be helpful since some patients (including some with left ventricular systolic dysfunction and some with rheumatic disease) have marked increases in mitral regurgitation and pulmonary artery pressures with exercise. In addition, stress echocardiography can detect reduced contractile reserve in some patients with severe mitral regurgitation and normal ejection fraction at rest. Stress echocardiography findings may have important therapeutic implications since, as noted in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular heart disease guidelines, mitral valve surgery is considered reasonable for asymptomatic patients with chronic severe mitral regurgitation and preserved left ventricular systolic function with pulmonary artery systolic pressure greater than 60 mm Hg with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Mitral valve surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography is indicated in the diagnostic evaluation of patients with left ventricular systolic dysfunction and low gradient aortic stenosis. Low gradient aortic stenosis has been defined as Doppler-derived aortic valve area less than 1.0 cm2 and mean gradient less than 30 mm Hg and is usually accompanied by left ventricular systolic dysfunction. Dobutamine infusion is started at 5",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    and increased at 5 minute intervals to 10 and 20",
"    <span class=\"nowrap\">",
"     mcg/kg/min.",
"    </span>",
"    Evaluation of low gradient stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Combination protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the main advantages of stress echocardiography is versatility. A skilled technician can combine the two-dimensional imaging and the Doppler evaluations in one or more views to follow ventricular function, cardiac output, left ventricular outflow tract gradients, transvalvular gradients, and pulmonary artery systolic pressure throughout graded exercise or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion. For example, stress-induced mitral regurgitation may be detected along with stress-induced wall motion abnormalities demonstrated by two-dimensional echocardiography. Lack of increase in peak Doppler aortic flow velocity during exercise may suggest left main or multivessel coronary artery disease. Development of left ventricular outflow tract obstruction during or shortly after exercise may elucidate a cause for symptoms of chest pain or dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116235003\">",
"    <span class=\"h2\">",
"     Technological advances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional echocardiography may be useful in the detection of ischemia, although live 3-D transthoracic imaging is not yet widely available in most laboratories. Other areas of ongoing research include strain and strain rate echocardiography, which may assist in the detection of myocardial ischemia and viability, and contrast perfusion echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35319/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10049073\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two major types of stress echocardiography are exercise (treadmill or bicycle) and pharmacologic (predominantly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) stress. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise stress is generally preferred to pharmacologic stress for patients who can perform an exercise test. Exercise echocardiography is most commonly performed using a treadmill protocol acquiring echocardiographic images prior to exercise and immediately after the peak treadmill exercise is completed. However, supine and upright bicycle ergometry are other well validated methods of exercise echocardiography, with the major advantage of allowing for monitoring of wall motion and Doppler parameters during exercise. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Exercise two-dimensional echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic stress is employed in patients who are unable to perform exercise testing. In addition, it may be preferred to exercise testing for preoperative risk and myocardial viability assessment since the majority of data validating stress echocardiography for this indication involved pharmacologic (largely",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) stress. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacologic stress echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Graded",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      infusion typically occurs in three-minute stages starting at 10",
"      <span class=\"nowrap\">",
"       mcg/kg/minute,",
"      </span>",
"      followed by 20, 30, and 40",
"      <span class=\"nowrap\">",
"       mcg/kg/minute.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      , in divided doses of 0.5 mg to a total of 2.0 mg, can be administered as needed to achieve the target heart rate. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dobutamine stress echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other stress echocardiography methods that have been investigated include atrial pacing and handgrip exercise. (See",
"      <a class=\"local\" href=\"#H10049168\">",
"       'Other stress methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stress echocardiography protocol that is chosen should be tailored to the indication for the test, with either exercise or pharmacologic stress being an option for most patients, but with one modality being preferred in certain specific clinical scenarios. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Protocols for specific indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/1\">",
"      Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/2\">",
"      Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008; 9:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/3\">",
"      Armstrong WF, Ryan T. Stress echocardiography from 1979 to present. J Am Soc Echocardiogr 2008; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/4\">",
"      Applegate RJ, Dell'Italia LJ, Crawford MH. Usefulness of two-dimensional echocardiography during low-level exercise testing early after uncomplicated acute myocardial infarction. Am J Cardiol 1987; 60:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/5\">",
"      Crouse LJ, Kramer PH. Exercise echocardiography: coming of age. J Am Coll Cardiol 1994; 24:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/6\">",
"      Peteiro J, Garrido I, Monserrat L, et al. Comparison of peak and postexercise treadmill echocardiography with the use of continuous harmonic imaging acquisition. J Am Soc Echocardiogr 2004; 17:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/7\">",
"      Bouzas-Mosquera A, Peteiro J, Alvarez-Garc&iacute;a N, et al. Prediction of mortality and major cardiac events by exercise echocardiography in patients with normal exercise electrocardiographic testing. J Am Coll Cardiol 2009; 53:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/8\">",
"      Park TH, Tayan N, Takeda K, et al. Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise. J Am Coll Cardiol 2007; 50:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/9\">",
"      Akosah KO, Mohanty PK. Role of dobutamine stress echocardiography in heart transplant patients. Chest 1998; 113:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/10\">",
"      Kamaran M, Teague SM, Finkelhor RS, et al. Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease. Am J Cardiol 1995; 76:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/11\">",
"      Elhendy A, Trocino G, Salustri A, et al. Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. Am Heart J 1996; 131:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/12\">",
"      Picano E, Mathias W Jr, Pingitore A, et al. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet 1994; 344:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/13\">",
"      Pi&eacute;rard LA, Berthe C, Albert A, et al. Haemodynamic alterations during ischaemia induced by dobutamine stress testing. Eur Heart J 1989; 10:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/14\">",
"      McNeill AJ, Fioretti PM, el-Said SM, et al. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992; 70:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/15\">",
"      Fioretti PM, Poldermans D, Salustri A, et al. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. Eur Heart J 1994; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/16\">",
"      Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/17\">",
"      Karagiannis SE, Bax JJ, Elhendy A, et al. Enhanced sensitivity of dobutamine stress echocardiography by observing wall motion abnormalities during the recovery phase after acute beta-blocker administration. Am J Cardiol 2006; 97:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/18\">",
"      Burger AJ, Notarianni MP, Aronson D. Safety and efficacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease. Am J Cardiol 2000; 86:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/19\">",
"      San Rom&aacute;n JA, Sanz-Ruiz R, Ortega JR, et al. Safety and predictors of complications with a new accelerated dobutamine stress echocardiography protocol. J Am Soc Echocardiogr 2008; 21:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/20\">",
"      Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 1997; 80:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/21\">",
"      Sicari R, Cortigiani L, Bigi R, et al. Prognostic value of pharmacological stress echocardiography is affected by concomitant antiischemic therapy at the time of testing. Circulation 2004; 109:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/22\">",
"      Picano E. Stress echocardiography. From pathophysiological toy to diagnostic tool. Circulation 1992; 85:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/23\">",
"      Picano E, Landi P, Bolognese L, et al. Prognostic value of dipyridamole echocardiography early after uncomplicated myocardial infarction: a large-scale, multicenter trial. The EPIC Study Group. Am J Med 1993; 95:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/24\">",
"      Picano E, Ostojic M, Varga A, et al. Combined low dose dipyridamole-dobutamine stress echocardiography to identify myocardial viability. J Am Coll Cardiol 1996; 27:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/25\">",
"      Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/26\">",
"      Borges AC, Richter WS, Witzel M, et al. Combined dipyridamole and dobutamine echocardiography in myocardial hibernation: comparison with thallium uptake in patients after percutaneous transluminal coronary revascularization under circulatory support. J Am Soc Echocardiogr 2001; 14:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/27\">",
"      Atar S, Nagai T, Cercek B, et al. Pacing stress echocardiography: an alternative to pharmacologic stress testing. J Am Coll Cardiol 2000; 36:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/28\">",
"      Rainbird AJ, Pellikka PA, Stussy VL, et al. A rapid stress-testing protocol for the detection of coronary artery disease: comparison of two-stage transesophageal atrial pacing stress echocardiography with dobutamine stress echocardiography. J Am Coll Cardiol 2000; 36:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/29\">",
"      Kobal SL, Pollick C, Atar S, et al. Stress echocardiography in octogenarians: transesophageal atrial pacing is accurate, safe, and well tolerated. J Am Soc Echocardiogr 2006; 19:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/30\">",
"      Perez-Gonzales JF, Schiller NB, Parmley WW. Direct and noninvasive evaluation of the cardiovascular response to isometric exercise. Circ Res 1981; 48:I138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/31\">",
"      Strizik B, Chiu S, Ilercil A, et al. Usefulness of isometric handgrip during treadmill exercise stress echocardiography. Am J Cardiol 2002; 90:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/32\">",
"      Khan IA, Otero FJ, Font-Cordoba J, et al. Adjunctive handgrip during dobutamine stress echocardiography: invasive assessment of myocardial oxygen consumption in humans. Clin Cardiol 2005; 28:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/33\">",
"      Bossone E, Rubenfire M, Bach DS, et al. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999; 33:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/34\">",
"      Schwammenthal E, Vered Z, Rabinowitz B, et al. Stress echocardiography beyond coronary artery disease. Eur Heart J 1997; 18 Suppl D:D130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/35\">",
"      Tischler MD, Niggel J. Exercise echocardiography in combined mild mitral valve stenosis and regurgitation. Echocardiography 1993; 10:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/36\">",
"      Zdrenghea D, Vlad C, Predescu D, Timi D. The correlation between Doppler data and effort capacity in mitral stenosis. Rom J Intern Med 1995; 33:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/37\">",
"      van den Brink RB, Verheul HA, Hoedemaker G, et al. The value of Doppler echocardiography in the management of patients with valvular heart disease: analysis of one year of clinical practice. J Am Soc Echocardiogr 1991; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/38\">",
"      Deng YB, Matsumoto M, Munehira J. Determination of mitral valve area in patients with mitral stenosis by the flow-convergence-region method during changing hemodynamic conditions. Am Heart J 1996; 132:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/39\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35319/abstract/40\">",
"      Cullen MW, Pellikka PA. Recent advances in stress echocardiography. Curr Opin Cardiol 2011; 26:379.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5310 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35319=[""].join("\n");
var outline_f34_31_35319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10049073\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXERCISE TWO-DIMENSIONAL ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Treadmill",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bicycle ergometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC STRESS ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dobutamine stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vasodilator stress testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10049168\">",
"      OTHER STRESS METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrial pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Handgrip exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROTOCOLS FOR SPECIFIC INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dyspnea of possible cardiac origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Combination protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116235003\">",
"      Technological advances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10049073\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41048?source=related_link\">",
"      Stress echocardiography: Indications, imaging techniques and safety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35320="Avian influenza vaccines";
var content_f34_31_35320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Avian influenza vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Iain Stephenson, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35320/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/31/35320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been five influenza pandemics during the past 100 years, and each has been caused by the emergence of a novel virus. In the 1957 and 1968 pandemics, the new viruses contained components of previous human as well as avian influenza viruses. The origin of the influenza virus responsible for the 1918 pandemic, which killed more people in a single year than the bubonic plague, remains uncertain, but it appears to have been an adapted avian influenza strain. The emergence of a novel H1N1 human-swine-avian reassortant virus in 2009 in North America resulted in a new pandemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic transmission of avian influenza H5N1 to more than 600 humans since 2003 have prompted concerns that conditions are suitable for emergence of a pandemic H5 influenza virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/1\">",
"     1",
"    </a>",
"    ]. Estimates of potential global mortality related to pandemic avian influenza are as high as 62 million deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to avian influenza vaccines will be reviewed here. Treatment and prevention of avian influenza (other than vaccination), and the epidemiology, transmission, pathogenesis, clinical manifestations, and diagnosis of avian influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization against avian influenza is an active area of research. A non-adjuvanted subvirion H5N1 influenza vaccine was approved by the United States Food and Drug Administration in April 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/2\">",
"     2",
"    </a>",
"    ]. An oil-in-water emulsion-adjuvanted subvirion H5N1 vaccine was approved for pre-pandemic use by the European Union in 2008. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Studies in humans'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Production of conventional H5N1 vaccine has been hampered by manufacturing difficulties and modest immunogenicity in humans. High priority research goals include improving production speed and increasing quantity of vaccine. Areas of research include use of cell culture systems, dose-sparing approaches (eg, whole virion formulation, intradermal administration) and use of adjuvants and live attenuated viruses to induce more robust immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Technical difficulties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Production of annual vaccines against human influenza requires bulk growth of influenza virus in embryonated hens' eggs. Use of highly pathogenic avian influenza viruses to produce vaccines by traditional methods is not feasible because of safety and technical reasons. The viruses are lethal to eggs, and cannot be grown in sufficient quantities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"     \"Seasonal influenza vaccination in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Work with highly pathogenic avian influenza viruses must be undertaken in biosecure facilities to protect workers and limit risks of environmental contamination. Manufacturing capacity to produce H5N1 vaccine is constrained by lack of biocontainment facilities and the requirement to also supply annual epidemic influenza vaccines.",
"   </p>",
"   <p>",
"    Alternative methods to vaccine production have been explored. One development in vaccine research has been the use of reverse genetics to create a well-matched nonpathogenic H5N1 virus that has high capacity to grow in eggs. However, manufacturers report that virus growth yields are lower than expected with reverse genetics-H5N1 viruses than with seasonal influenza viruses, reducing the amount of antigen able to be used for vaccine formulation.",
"   </p>",
"   <p>",
"    Another method that avoids the problem of virus lethality to eggs is to grow H5N1 virus in cell culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/4\">",
"     4",
"    </a>",
"    ]. A whole-virion vaccine produced using this technique has proven to be well tolerated and immunogenic in a trial described below. An additional potential benefit of this approach is that the production of a vaccine would not be limited by the time constraints of using embryonated eggs, which may have limited availability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Whole-virion H5N1 vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the event of a pandemic, there would be enormous worldwide demand for vaccine. It is essential that pandemic planning strategies include clinical assessment of avian influenza virus vaccine candidates with potential adjuvants and delivery systems to optimize use of available antigenic material in advance of a pandemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Manufacturing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2005, the global manufacturing capacity of seasonal trivalent influenza vaccines (containing 15 mcg per strain) was approximately 400 million doses per year. Assuming that people require two doses of monovalent vaccine, the available doses will be approximately 600 million. If 90 mcg (six times the normal dose) is needed, then the available number of doses drops to only 100 million. By using 30 mcg (twice the normal dose) in an alum-adjuvanted vaccine, the number of available dose increases to 300 million. This supply will need to be shared among a global population of 6 billion. Increasing seasonal vaccine demand and recent investment in production facilities have led to increased global manufacturing capacity; however, significant shortfalls remain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANIMAL MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models have been invaluable for the development of avian influenza vaccines, particularly since it is possible to test not only immunogenicity but also clinical efficacy against a challenge of avian influenza virus. Various avian influenza vaccines have shown promising results in animal models, including inactivated vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/8\">",
"     8",
"    </a>",
"    ], live attenuated vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/9\">",
"     9",
"    </a>",
"    ], vector-based vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/10\">",
"     10",
"    </a>",
"    ], vaccines produced using reverse genetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], plasmid DNA vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/14\">",
"     14",
"    </a>",
"    ], a DNA vaccine that encodes virus-like particles (VLPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/15\">",
"     15",
"    </a>",
"    ], and a computationally optimized hemagglutinin VLP vaccine that was designed to elicit broadly reactive immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, strategies that include adjuvants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/17\">",
"     17",
"    </a>",
"    ], a lipid delivery system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/14\">",
"     14",
"    </a>",
"    ], or a prime-boost regimen have demonstrated efficacy in such models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STUDIES IN HUMANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple avian influenza vaccines are currently being evaluated and one vaccine has been approved by the United States Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/2\">",
"     2",
"    </a>",
"    ]. Although there have been few direct comparisons among vaccine formulations, it is now clear that oil-in-water emulsion-adjuvanted and whole virion H5N1 influenza vaccines offer advantages over conventional subvirion vaccines. An oil-in-water emulsion (AS03) adjuvanted H5N1 vaccine has been approved for use in the European Union [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major problem with the development of an effective vaccine against avian influenza (and H5, in particular) has been poor immunogenicity in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Another significant issue is that the serology tests used as measures of immunogenicity for influenza vaccines are not standardized and display marked variation among laboratories. As a result, caution must be used when comparing results from different studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/22\">",
"     22",
"    </a>",
"    ]. International standards for detecting antibody to clade 1 H5 antigens have been established by WHO and will help standardize vaccine immunogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Non-adjuvanted H5N1 vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter randomized trial, the safety and efficacy of a non-adjuvanted subvirion influenza H5N1 vaccine was evaluated in 451 healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/24\">",
"     24",
"    </a>",
"    ]. Participants received two doses of vaccine containing 90, 45, 15, or 7.5 mcg of hemagglutinin antigen or placebo. Although the vaccine was safe, immunogenicity was only modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/25\">",
"     25",
"    </a>",
"    ]. The only group in which more than 50 percent of subjects reached the predefined threshold for immunogenicity occurred with administration of 90 mcg, a total dose nearly 12 times that of seasonal influenza vaccines. The vaccine was well tolerated; the most common side effects were pain at the injection site, headache, malaise, and muscle pain.",
"   </p>",
"   <p>",
"    This vaccine was approved by the FDA in April 2007. The vaccine is intended for use in adults from 18 to 65 years of age and is given as two doses one month apart. The vaccine will not be sold commercially; instead it will be purchased by the United States government for inclusion in the National Stockpile for distribution by public health officials, as needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a follow-up study published subsequent to the FDA approval, 337 participants received a third dose of vaccine containing 90, 45, 15, or 7.5 mcg of hemagglutinin antigen. Microneutralization geometric mean titers were &ge;1:40 in 78, 67, 43, and 31 percent of recipients in each group, respectively, one month after the third dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/27\">",
"     27",
"    </a>",
"    ]. Five months later, microneutralization geometric mean titers were significantly greater than titers after the second dose. Another study showed that individuals who received three or four doses of a non-adjuvanted inactivated H5N1 vaccine achieved higher hemagglutination inhibition and microneutralization geometric mean titers compared with those who received fewer doses, although there was no benefit to increasing the dose of the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, 37 individuals who had been vaccinated eight years earlier with a recombinant hemagglutinin H5N1 vaccine received a single intramuscular injection of an inactivated subvirion H5N1 vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/29\">",
"     29",
"    </a>",
"    ]. A higher percentage of those who had been vaccinated previously responded to the vaccine (73 versus 41 percent) and had microneutralization geometric mean titers &ge;1:40 (73 versus 42 percent) compared with H5-naive individuals who received two doses of the inactivated subvirion A H5N1 vaccine. This study suggests that a prime-boost strategy could enhance the immunogenicity of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/17/21780?source=see_link\">",
"     avian influenza vaccine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    There is interest in the immunogenicity of administering two doses of H5N1 vaccines with a short interval between doses since such a strategy could be beneficial following a pandemic declaration when rapid protection is required. In a study in which non-adjuvanted subvirion H5N1 vaccines containing clade 1 or clade 2 antigens were administered 7, 14, 28, or 180 days apart as a heterologous prime-boost regimen, the accelerated schedule of vaccines administered on days 0 and 14 was as immunogenic as a schedule of vaccines on days 0 and 28, but both schedules were less immunogenic than a schedule of vaccines on days 0 and 180 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/30\">",
"     30",
"    </a>",
"    ]. The schedule that involved doses on days 0 and 7 was the least immunogenic. The use of an accelerated schedule has also been evaluated for oil-in-water adjuvanted vaccines. (See",
"    <a class=\"local\" href=\"#H992551272\">",
"     'Oil-in-water emulsion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjuvanted H5N1 candidate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvantation enables lower doses of antigen to be given, which has the potential to increase production capacity of pandemic influenza vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Oil-in-emulsion adjuvanted vaccines, but not alum-adjuvanted vaccines, are associated with better overall immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/19,33-37\">",
"     19,33-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these \"antigen-sparing\" approaches have used subvirion versus whole virion vaccine design.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subvirion H5N1 vaccines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992551264\">",
"    <span class=\"h4\">",
"     Aluminum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aluminum adjuvanted avian influenza vaccines have induced only modest antibody responses compared with non-adjuvanted vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/7,33,36\">",
"     7,33,36",
"    </a>",
"    ]. As an example, in a randomized trial, 600 adults received two doses one month apart of subvirion inactivated influenza",
"    <span class=\"nowrap\">",
"     A/H5N1",
"    </span>",
"    vaccine containing 7.5, 15, or 45 mcg of hemagglutinin (HA) with or without 600 mcg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    (AlOH), or 3.75 mcg of HA with or without 300 mcg of AlOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the first dose of vaccine, there were no differences between those who received adjuvanted and non-adjuvanted vaccines and there was only a modest improvement in immunogenicity after the second dose in those who received 7.5 mcg of HA with AlOH.",
"   </p>",
"   <p>",
"    After the second dose of vaccine, 8 of 59 individuals (14 percent) who received 7.5 mcg of HA with AlOH developed a &ge;4-fold increase in hemagglutinin inhibition titer compared with none of those who received the same dose of non-adjuvanted vaccine. Fourteen of 59 (24 percent) of those who received 7.5 mcg HA with AlOH developed a &ge;4-fold increase in neutralizing antibodies compared with 5 of 55 individuals (8 percent) who received non-adjuvanted vaccine at the same dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992551272\">",
"    <span class=\"h4\">",
"     Oil-in-water emulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two recombinant H5N1 subvirion vaccines were administered 21 days apart to 400 healthy volunteers 18 to 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/34\">",
"     34",
"    </a>",
"    ]. Four antigen doses (3.8, 7.5, 15, and 30 mcg hemagglutinin) with or without a novel oil-in-water emulsion adjuvant (AS03) were administered to eight groups of study participants. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the first adjuvanted vaccine dose, all doses of 7.5 mcg and higher led to adequate neutralizing antibody responses and seroconversion titers, as defined by standard European and United States criteria.",
"     </li>",
"     <li>",
"      After the second adjuvanted vaccine dose, all doses (including the lowest antigen dose of 3.8 mcg), met these criteria.",
"     </li>",
"     <li>",
"      The non-adjuvanted vaccines were poorly immunogenic except for the highest antigen dose (30 mcg), which led to adequate neutralizing antibody titers and seroconversion rates only after the second dose of vaccine.",
"     </li>",
"     <li>",
"      Among participants receiving 3.8 mcg of adjuvanted vaccine, 37 of 48 (77 percent) developed neutralizing antibodies against a drifted H5N1 strain, consistent with cross-clade immunity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these results, this antigen-sparing oil-in-water emulsion-adjuvanted H5N1 vaccine has been licensed for use in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent trial demonstrated that a two-dose regimen of an even lower dose (1.9 mcg) of oil-in-water emulsion adjuvanted hemagglutinin H5N1 vaccine was more immunogenic (92 percent had a fourfold increase in microneutralization titers versus 42 percent) and induced a higher proportion of cross-neutralizing antibodies (39 to 65 percent versus 7 percent) compared with 7.5 mcg of non-adjuvanted vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In individuals &gt;61 years of age, a two dose series of 7.5 mcg of oil-in-water emulsion-adjuvanted vaccine given 21 days apart resulted in higher hemagglutinin inhibition and neutralizing antibody titers than a two dose series of 3.75 mcg of the same vaccine, although both dosing regimens met the European Committee for Human Medicinal Products criteria for seroconversion and seroprotection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another trial that included adults and elderly adults, two doses of an oil-in-water emulsion-adjuvanted clade 2.1 H5N1 vaccine containing 3.75 mcg of the HA antigen given 21 days apart were highly immunogenic for the homologous virus, and induced cross-clade immune responses against clade 1 viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As stated above, there is interest in the immunogenicity of administering two doses of H5N1 vaccines with a short interval between doses since such a strategy could be beneficial if used during a pandemic (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Non-adjuvanted H5N1 vaccine'",
"    </a>",
"    above). In one trial, adults aged 18 to 64 years were randomly assigned to receive an oil-in-water adjuvanted subvirion vaccine that contained 3.75 mcg of the HA antigen 21 days apart (standard schedule), 14 days apart, 7 days apart, or on the same day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/41\">",
"     41",
"    </a>",
"    ]. Although the highest hemagglutinin inhibition titers against the homologous strain of virus were observed with the standard schedule, each of the accelerated schedules met predetermined immunogenicity licensing criteria. Immune responses against drifted variants of H5N1 influenza virus were best with the 21 and 14 day dosing intervals, but were lower with the 7 day and same day dosing schedules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992551305\">",
"    <span class=\"h4\">",
"     MF59",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared a two-dose regimen of an H5N1 vaccine in 394 healthy subjects who received either placebo or vaccine alone at 45, 30, or 15 mcg per dose; vaccine at 15 or 7.5 mcg per dose was adjuvanted with MF59; or vaccine at 30, 15, or 7.5 mcg per dose was adjuvanted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/35\">",
"     35",
"    </a>",
"    ]. One month after the second dose, the end-point of a hemagglutination inhibition titer &ge;40 was achieved significantly more often with a 15 mcg dose of the MF59-adjuvanted vaccine compared to a 45 mcg dose of non-adjuvanted vaccine (63 versus 29 percent). The aluminum hydroxide adjuvanted vaccine did not provide additional benefit compared with the non-adjuvanted vaccine.",
"   </p>",
"   <p>",
"    In another trial, 40 healthy adults were vaccinated with MF59-adjuvanted H5N1 subunit vaccine (at a dose of 7.5 or 15 mcg) or non-adjuvanted H5N1 subunit vaccine (at a dose of 15 mcg) administered on days 1, 22, and 202; the vaccines were produced using reverse genetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/42\">",
"     42",
"    </a>",
"    ]. Only the MF59-adjuvanted vaccine elicited high titers of neutralizing antibodies, a large pool of H5N1-specific memory B cells, and CD4+ T cells that were broadly reactive with drifted H5. A threefold increase in the frequency of H5-specific CD4+ T cells measured after the first dose of vaccine predicted the rise in neutralizing antibodies after booster immunization as well as their persistence six months later. Similar findings were observed in a trial of a virosomal vaccine (see",
"    <a class=\"local\" href=\"#H344329106\">",
"     'Virosomal vaccine'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/43\">",
"     43",
"    </a>",
"    ]. Although a larger trial is needed to confirm these findings, this trial suggests that the CD4+ T cell response serves as an early marker of immunogenicity.",
"   </p>",
"   <p>",
"    A trial was performed to assess whether the concomitant use of an H5N1 influenza vaccine and a seasonal influenza vaccine would be immunogenic and safe; 401 healthy adults were randomly assigned to receive MF59-adjuvanted H5N1 vaccine as a mixed injection with a non-adjuvanted inactivated seasonal influenza vaccine, simultaneous separate injections of the H5N1 and seasonal influenza vaccines, or a single injection of either the H5N1 or the seasonal influenza vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/44\">",
"     44",
"    </a>",
"    ]. When administered as either a mixed injection or as simultaneous separate injections, both the H5N1 and the seasonal influenza vaccines were as immunogenic and safe as either vaccine given alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Whole-virion H5N1 vaccines",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized phase I clinical trial evaluated the safety and immunogenicity of four different formulations of an alum-adjuvanted whole-virion H5N1 vaccine in 120 volunteers in China [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/45\">",
"       45",
"      </a>",
"      ]. The formulation with the best immunogenicity, as measured by neutralizing and hemagglutinin-inhibition responses, was the 10 mcg group after two vaccine doses. These data suggest that use of whole-virion vaccines may allow a dose-sparing approach, while achieving high levels of protective efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/46\">",
"       46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a follow-up study, subjects were found to have markedly diminished antibody levels 12 months after the second dose of vaccine, but one month following a third dose of vaccine (5 or 10 mcg) most patients developed strong boosted antibody responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized phase II trial evaluated the safety, immunogenicity, and cross-reactivity of an inactivated alum-adjuvanted whole-virion H5N1 vaccine in volunteers in China [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/48\">",
"       48",
"      </a>",
"      ]. Two doses of vaccine containing 5, 10, or 15 mcg of hemagglutinin were given to 301 volunteers 28 days apart; two doses of 10 mcg of vaccine were given to 101 volunteers 14 days apart. The highest antibody responses were seen in those who received 15 mcg of vaccine, with 90 and 100 percent of subjects having a titer &ge;1:40 by hemagglutination inhibition and microneutralization assays, respectively. Higher antibody responses were elicited in those who were vaccinated 28 days apart than in those who were vaccinated 14 days apart. After two doses of 10 mcg of vaccine, 98 and 87 percent of subjects had a microneutralization titer of &ge;1:40 against two heterologous H5N1 strains.",
"     </li>",
"     <li>",
"      A randomized, dose-escalation, phase I and II trial evaluated the safety and immunogenicity of a Vero cell-derived whole-virion H5N1 vaccine in 275 volunteers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/4\">",
"       4",
"      </a>",
"      ]. Subjects received two doses of vaccine 21 days apart that each contained 3.75 mcg, 7.5 mcg, 15 mcg, or 30 mcg of hemagglutinin (HA) antigen with alum-adjuvant, or 7.5 or 15 mcg of HA antigen without adjuvant. The vaccine induced neutralizing antibodies against the clade 1 virus strain used in the vaccine, and also against clade 2 and 3 strains.",
"      <br/>",
"      <br/>",
"      The maximum responses occurred in those who received the formulations containing 7.5 mcg or 15 mcg of the HA antigen without adjuvant, in whom 76 and 71 percent of subjects had a neutralizing antibody titer &ge;1:20 on day 42 compared with 61 to 69 percent of those who received the adjuvanted vaccine. This trial suggests that a non-adjuvanted whole-virion vaccine is a promising candidate H5N1 vaccine because of its favorable immunogenicity. Furthermore, the mode of production (in Vero cell cultures) has potential advantages. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technical difficulties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a follow-up study, a subset of the individuals in the original trial received a booster containing 7.5 mcg of the HA antigen without adjuvant from a clade 2.1 strain 12 to 17 months after the priming regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/49\">",
"       49",
"      </a>",
"      ]. The prime-boost regimen resulted in higher antibody responses against clades 1, 2.1, 2.2, and 2.3 viruses than those induced after the priming regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344329106\">",
"    <span class=\"h3\">",
"     Virosomal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase I trial of 60 adults who received two doses of a virosomal H5N1 vaccine adjuvanted with the immunostimulating complex Matrix M, the vaccine effectively induced CD4+ Th1 cell responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, the frequency of influenza-specific Th1 cells after the first dose of vaccine predicted subsequent seroprotective immune responses (measured by hemagglutinin inhibition, microneutralization, and single radial hemolysis assays) after the second dose of vaccine. These results suggest that Th1 cell responses may serve as a predictive biomarker for an effective humoral immune response. Similar findings were observed in a trial of an MF59-adjuvanted H5N1 vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H992551305\">",
"     'MF59'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjuvanted H5N3 candidate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to induce and boost antibody responses that are cross-reactive to future emerging H5 strains would be beneficial in a strategy in which at risk individuals are vaccinated prior to a pandemic. Before the adoption of reverse genetics to attenuate the virulence of H5N1 viruses, an approach used was to develop adjuvanted candidate vaccines based upon a nonpathogenic influenza variant, H5N3 influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/19,20,31,50\">",
"     19,20,31,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinical trial of MF59 or non-adjuvanted H5N3 vaccine (7.5, 15, and 30 mcg hemagglutinin) found that two doses of the adjuvanted vaccine induced neutralizing antibody titers and seroconversions, whereas the non-adjuvanted vaccine resulted in poor antibody responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/31\">",
"     31",
"    </a>",
"    ]. A third dose of the same vaccine formulation 16 months later induced broadly cross-reactive immune responses to a range of wild-type H5N1 virus variants. Again, the non-adjuvanted vaccine was associated with poor antibody responses.",
"   </p>",
"   <p>",
"    In an open-label study, 24 subjects who had been primed with non-adjuvanted or MF59-adjuvanted H5N3 vaccines in clinical trials were boosted up to seven years later with an antigenically distinct single low dose (7.5 mcg) of MF59-adjuvanted H5N1 vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/50\">",
"     50",
"    </a>",
"    ]. Comparator subjects (n = 30) were those who had not previously received H5 vaccine. Sera were taken at days 7, 14, 21, and 42 after boosting, and antibody titers to all known human H5 virus variants were measured. Among primed subjects, there was a higher response rate to all strains than in the unprimed subjects. Subjects primed with MF59-adjuvanted vaccine had higher response rates than those primed with non-adjuvanted vaccine. At day 7 after boosting, over 80 percent of MF59-primed subjects had protective neutralizing titers to all strains tested. In addition, significant numbers of cross-reactive H5-specific memory B cells were induced by the booster dose, suggesting that pre-pandemic priming would induce long-lasting memory responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     H9N2 candidate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;H9N2 vaccine candidates have been assessed in several studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Non-adjuvanted H9N2 vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom, healthy adults aged 18 to 60 years were randomly assigned two doses of inactivated whole virus or subunit",
"    <span class=\"nowrap\">",
"     A/Hong",
"    </span>",
"    <span class=\"nowrap\">",
"     Kong/1073/99",
"    </span>",
"    (H9N2) vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/21\">",
"     21",
"    </a>",
"    ]. More than 40 percent of prevaccination serum samples had detectable anti-H9N2 reactivity, suggesting cross-reactivity from exposure to earlier circulation hemagglutinins. Consequently, subjects could be divided into those who were immunologically naive or primed.",
"   </p>",
"   <p>",
"    For primed individuals, one dose of either vaccine was sufficient to boost anti-H9 responses. However, in naive subjects, one dose of either vaccine was poorly immunogenic. Although whole virus vaccine was more immunogenic than subunit vaccine, the majority of subjects failed to achieve seroprotective HI titers of 1:40 after two doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adjuvanted H9N2 vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted for the H5N1 vaccines, the use of adjuvanted vaccine is associated with greater immunogenicity and allows for a lower dose of antigen to be used in vaccine design.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase I double-blind, randomized trial, the safety and immunogenicity of inactivated H9N2 vaccine was evaluated with and without MF59 adjuvant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/52\">",
"       52",
"      </a>",
"      ]. Geometric mean serum hemagglutination inhibition and microneutralization antibody assays demonstrated that one dose of adjuvanted vaccine produced similar titers as two doses of non-adjuvanted vaccine.",
"     </li>",
"     <li>",
"      In another study, alum-adjuvanted whole virus",
"      <span class=\"nowrap\">",
"       A/Hong",
"      </span>",
"      <span class=\"nowrap\">",
"       Kong/1073/99",
"      </span>",
"      (H9N2) vaccine was compared to monovalent alum-adjuvanted vaccine containing either 7.5, 3.8, or 1.9 mcg H9 hemagglutinin was compared with plain whole virus 15 mcg vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/32\">",
"       32",
"      </a>",
"      ]. The use of alum in vaccine preparation allowed a reduction in H9 content to 1.9 mcg per dose, while maintaining immunogenicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Live attenuated H9N2 vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open-label study of a live attenuated H9N2 vaccine, 92 percent of H9-seronegative individuals had &ge;4-fold increases in hemagglutination inhibition antibody and 79 percent had &ge;4-fold increases in neutralizing antibody after two doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/53\">",
"     53",
"    </a>",
"    ]. The vaccine was well tolerated and vaccine shedding was minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VACCINE EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if the antibodies produced by these vaccines will afford sufficient protection in the event of a pandemic and there are no data on vaccine efficacy in young, elderly, or immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FUTURE TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies assessing novel adjuvants and formulations of pandemic influenza vaccines are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple clinical trials assessing pandemic vaccine candidates have been conducted or are underway, including inactivated egg-grown subunit and whole-virion vaccine, cell-culture derived vaccine, adjuvanted (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      , aluminum phosphate, polyoxidonium and MF59), and live attenuated virus formulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessments of subunit, adjuvanted, virosomal, and whole-virus H7 and H9 vaccine candidates are being performed. One trial will employ a needle-free vaccine delivery system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRE-PANDEMIC STOCKPILING AND VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several options available for the use of pandemic H5N1 influenza vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Because future pandemic strains are unknown, a well-matched and so-called \"pandemic-specific\" vaccine cannot be produced until the virus has emerged and been characterized. Limitations in vaccine production capacity as well as the logistics of distribution and administration are likely to delay widespread availability of pandemic-specific vaccine for several months following the onset of a pandemic.",
"   </p>",
"   <p>",
"    Pre-pandemic vaccine production and stockpiling may, in part, offset vaccine availability limitations. Some governments, including that of the United States, have stockpiled H5N1 vaccine as part of their preparedness planning. However, antigenic diversity of circulating H5N1 viruses and uncertainty of the next pandemic virus subtype mean that vaccine prepared in advance of the pandemic may not be well-matched to the eventual outbreak strain. Furthermore, even if stockpiles of pre-prepared influenza antigen are held, this may not address limitations in adjuvant availability or secondary manufacturing issues such as syringe filling and vaccine formulation. Defining the highest risk groups for vaccination campaigns during a pandemic will depend upon several factors, including which age groups are most affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach that has been proposed is pre-pandemic vaccine administration to specific segments of the population. Administration of pre-pandemic H5 vaccine might induce long-acting memory responses that could be boosted by single revaccination in the future or even by exposure to the emergent virus itself. Priming subjects with MF59-adjuvanted H5N3 vaccine, and boosting many years later with antigenically distinct heterologous H5N1 vaccine provides evidence that this is a viable approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Similarly, a heterologous prime-boost regimen of a whole-virion H5N1 vaccine with a booster given 12 to 17 months after the priming regimen resulted in higher antibody responses than the priming regimen alone, as well as cross-reactive antibodies to related clades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adjuvanted H5N3 candidate vaccines'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Whole-virion H5N1 vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, the widespread use of pre-pandemic vaccine among the population must be balanced with the risk of unexpected adverse reactions. This approach should be considered first in those at higher risk of exposure to pandemic influenza, such as healthcare workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35320/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public health issues related to avian influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and prevention of avian influenza\", section on 'Public health perspective'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic transmissions of avian influenza H5N1 to more than 600 humans since 2003 have prompted concerns that conditions are suitable for emergence of a pandemic H5 influenza virus. Estimates of potential global mortality related to pandemic avian influenza are as high as 62 million deaths. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Production of conventional H5N1 vaccine has been hampered by manufacturing difficulties and modest immunogenicity in humans. High priority research goals include improving production speed and increasing quantity of vaccine. Areas of research include use of cell culture systems, dose-sparing approaches (eg, whole virion formulation, intradermal administration) and use of adjuvants and live attenuated viruses to elicit more robust immune responses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General concepts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A non-adjuvanted subvirion H5N1 influenza vaccine was approved by the United States Food and Drug Administration in April 2007. An oil-in-water emulsion-adjuvanted subvirion H5N1 vaccine was approved for pre-pandemic use by the European Union in 2008. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General concepts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there have been few direct comparisons among vaccine formulations, it is now clear that oil-in-water emulsion-adjuvanted and whole virus H5N1 influenza vaccines offer advantages over conventional subvirion vaccines. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Studies in humans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some governments, including that of the United States, have stockpiled H5N1 vaccine as part of their pandemic preparedness planning. However, antigenic diversity of circulating H5N1 viruses and uncertainty of the next pandemic virus subtype mean that vaccine prepared in advance of the pandemic may not be well-matched to the eventual outbreak strain. Another approach that has been proposed is pre-pandemic vaccine administration to specific segments of the population. Administration of pre-pandemic H5 vaccine might induce long-acting memory responses that could be boosted by single revaccination in the future or even by exposure to the emergent virus itself. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pre-pandemic stockpiling and vaccination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. file://www.who.int/influenza/human_animal_interface/EN_GIP_20130215CumulativeNumberH5N1cases.pdf (Accessed on February 20, 2013).",
"    </li>",
"    <li>",
"     FDA News. FDA approves first US vaccine for humans against the avian influenza virus H5N1 file://www.fda.gov/bbs/topics/NEWS/2007/NEW01611.html (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/3\">",
"      Bartlett JG. Planning for avian influenza. Ann Intern Med 2006; 145:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/4\">",
"      Ehrlich HJ, M&uuml;ller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/5\">",
"      Wright PF. Vaccine preparedness--are we ready for the next influenza pandemic? N Engl J Med 2008; 358:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/6\">",
"      Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/7\">",
"      Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/8\">",
"      Lipatov AS, Hoffmann E, Salomon R, et al. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006; 194:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/9\">",
"      Gustin KM, Maines TR, Belser JA, et al. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J Infect Dis 2011; 204:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/10\">",
"      Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/11\">",
"      Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/12\">",
"      Lipatov AS, Webby RJ, Govorkova EA, et al. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005; 191:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/13\">",
"      Takahashi Y, Hasegawa H, Hara Y, et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009; 199:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/14\">",
"      Lalor PA, Webby RJ, Morrow J, et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008; 197:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/15\">",
"      Sz&eacute;csi J, Gabriel G, Edfeldt G, et al. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J Infect Dis 2009; 200:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/16\">",
"      Giles BM, Crevar CJ, Carter DM, et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 2012; 205:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/17\">",
"      Ichinohe T, Tamura S, Kawaguchi A, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007; 196:1313.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency file://www.emea.europa.eu/humandocs/Humans/EPAR/prepandrix/prepandrix.htm (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/19\">",
"      Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/20\">",
"      Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/21\">",
"      Stephenson I, Nicholson KG, Gl&uuml;ck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/22\">",
"      Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:4056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/23\">",
"      Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009; 15:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/24\">",
"      Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/25\">",
"      Poland GA. Vaccines against avian influenza--a race against time. N Engl J Med 2006; 354:1411.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Press Announcements file://www.fda.gov/bbs/topics/NEWS/2007/NEW01611.html. (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/27\">",
"      Zangwill KM, Treanor JJ, Campbell JD, et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/28\">",
"      Beigel JH, Voell J, Huang CY, et al. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 2009; 200:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/29\">",
"      Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/30\">",
"      Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011; 203:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/31\">",
"      Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/32\">",
"      Hehme N, Engelmann H, K&uuml;nzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/33\">",
"      Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/34\">",
"      Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/35\">",
"      Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/36\">",
"      Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008; 198:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/37\">",
"      Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/38\">",
"      Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/39\">",
"      Heijmans S, De Meulemeester M, Reynders P, et al. Immunogenicity profile of a 3.75-&mu;g hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/40\">",
"      Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/41\">",
"      Lasko B, Reich D, Madan A, et al. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/42\">",
"      Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/43\">",
"      Pedersen GK, Madhun AS, Breakwell L, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/44\">",
"      Lopez P, Caicedo Y, Sierra A, et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J Infect Dis 2011; 203:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/45\">",
"      Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/46\">",
"      Stephenson I. H5N1 vaccines: how prepared are we for a pandemic? Lancet 2006; 368:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/47\">",
"      Lin JT, Li CG, Wang X, et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis 2009; 199:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/48\">",
"      Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 48:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/49\">",
"      Ehrlich HJ, M&uuml;ller M, Fritsch S, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/50\">",
"      Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/51\">",
"      Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 2009; 106:7962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/52\">",
"      Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006; 43:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/53\">",
"      Karron RA, Callahan K, Luke C, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009; 199:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/54\">",
"      Fauci AS. Race against time. Nature 2005; 435:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/55\">",
"      Ahmad, S. Avian flu vaccine trials. Nature Reviews Immunology 2006; 6:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/56\">",
"      Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science 2012; 336:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/57\">",
"      Miller MA, Viboud C, Olson DR, et al. Prioritization of influenza pandemic vaccination to minimize years of life lost. J Infect Dis 2008; 198:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35320/abstract/58\">",
"      Jennings LC, Monto AS, Chan PK, et al. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7000 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35320=[""].join("\n");
var outline_f34_31_35320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Technical difficulties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Manufacturing capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANIMAL MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STUDIES IN HUMANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Non-adjuvanted H5N1 vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjuvanted H5N1 candidate vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subvirion H5N1 vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H992551264\">",
"      Aluminum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H992551272\">",
"      Oil-in-water emulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H992551305\">",
"      MF59",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Whole-virion H5N1 vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344329106\">",
"      - Virosomal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjuvanted H5N3 candidate vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      H9N2 candidate vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Non-adjuvanted H9N2 vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adjuvanted H9N2 vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Live attenuated H9N2 vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VACCINE EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FUTURE TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRE-PANDEMIC STOCKPILING AND VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PUBLIC HEALTH PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35321="Neonatal herpes simplex virus infection: Clinical features and diagnosis";
var content_f34_31_35321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Gail J Demmler-Harrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/31/35321/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/31/35321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal infection with herpes simplex virus (HSV) occurs in 1 out of every 3200 to 10,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], causes serious morbidity and mortality, and leaves many survivors with permanent sequelae. Despite this seemingly low prevalence, neonatal HSV accounts for 0.2 percent of neonatal hospitalizations and 0.6 percent of in-hospital neonatal deaths in the United States, and is associated with substantial healthcare resource utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the discovery of neonatal HSV disease in the 1930s, important breakthroughs in understanding how HSV is transmitted to the fetus and neonate, molecular methods to diagnose HSV, and antiviral treatment strategies have improved diagnosis and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. However, despite these advances, neonatal HSV remains a clinical challenge.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of neonatal HSV infection will be reviewed below. The management, outcome, and prevention of neonatal HSV infection and nonneonatal herpes simplex virus infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=see_link\">",
"     \"Herpetic gingivostomatitis in young children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) is a member of the",
"    <em>",
"     Herpesviridae",
"    </em>",
"    family of viruses. It contains a double-stranded linear DNA genome that consists of 150,000 base pairs that encode for more than 80 polypeptides, a capsid consisting of 162 capsomeres arranged in icosahedral symmetry that is covered by a tightly adherent membranous tegument, and an envelope consisting of 11 glycoproteins (gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL, and gM), lipids, and polyamines that surrounds the viral nucleocapsid (",
"    <a class=\"graphic graphic_picture graphicRef81175 \" href=\"mobipreview.htm?36/45/37586\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. Like all",
"    <em>",
"     Herpesviridae",
"    </em>",
"    viruses, HSV shares the biological properties of latency and reactivation, which causes recurrent infections in the host.",
"   </p>",
"   <p>",
"    HSV enters the human host through inoculation of oral, genital, or conjunctival mucosa or breaks in skin, infects the sensory nerve endings, and then transports via retrograde axonal flow to the dorsal root ganglia, where it remains for the life of the host. The fetus may be infected transplacentally or through retrograde spread through ruptured or seemingly intact membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. Latent virus is not susceptible to antiviral drugs, and infection, even after antiviral therapy, is lifelong. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H13#H13\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV replicates efficiently in cell cultures, quickly producing lytic cytopathic effect in one to three days in most cell lines used in clinical virology laboratories (",
"    <a class=\"graphic graphic_picture graphicRef72209 \" href=\"mobipreview.htm?43/27/44471\">",
"     picture 2",
"    </a>",
"    ). The virus can be typed into HSV type 1 and HSV type 2 using serologic and molecular techniques. The DNA of HSV-1 and HSV-2 contain many homologous sequences distributed over the entire genome of both types, which produce both unique (gG) and antigenically similar polypeptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. This cross-reactivity between HSV-1 and HSV-2 glycoproteins is the reason most commercially available serologic assays cannot distinguish between HSV-1 and HSV-2 antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of neonatal herpes simplex virus (HSV) infection is estimated to be between 1 in 3000 and 1 in 20,000 births, with most current estimates ranging close to 1 in 3200 to 10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There are an estimated 1500 cases of neonatal HSV infection annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ]. As the baseline prevalence of HSV-2 genital infection increases in the general population, the incidence of neonatal HSV disease is also likely to increase. Some experts feel the incidence of severe neonatal HSV disease, including disseminated and CNS disease, has increased since 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal HSV has three distinct periods of acquisition: intrauterine, perinatal, and postnatal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intrauterine",
"      </strong>",
"      &ndash; Intrauterine HSV occurs rarely (estimated incidence of 1 in 250,000 deliveries).",
"     </li>",
"     <li>",
"      <strong>",
"       Perinatal",
"      </strong>",
"      &ndash; The majority (85 percent) of neonatal HSV infections are acquired perinatally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"       9",
"      </a>",
"      ]. HSV is acquired perinatally when HSV infection, either symptomatic or asymptomatic, is present in the genital tract of the pregnant woman at the time of delivery. Factors that may influence perinatal transmission include the type of maternal HSV infection (primary versus recurrent), maternal HSV antibody status, duration of ruptured membranes, use of fetal scalp monitors, and mode of delivery (cesarean versus vaginal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/11\">",
"       11",
"      </a>",
"      ]. However, most neonates with HSV disease are born to mothers without a history of HSV infection or other identifiable risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"       \"Genital herpes simplex virus infection and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Postnatal",
"      </strong>",
"      &ndash; Approximately 10 percent of neonatal HSV infections are acquired postnatally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"       9",
"      </a>",
"      ]. Postnatal acquisition of neonatal HSV occurs when a caretaker with active HSV infection, such as herpes labialis, has close contact with the newborn infant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intrauterine HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine or congenital herpes simplex virus (HSV) infection is rare. It is most likely caused by maternal viremia associated with primary HSV infection during pregnancy. Intrauterine HSV is associated with placental infarcts and necrotizing, calcifying funisitis (inflammation of the umbilical cord), hydrops fetalis, and fetal in utero demise. Survivors of in utero HSV infection may exhibit a characteristic triad of skin vesicles, ulcerations, or scarring (",
"    <a class=\"graphic graphic_picture graphicRef55645 \" href=\"mobipreview.htm?6/28/6597\">",
"     picture 3",
"    </a>",
"    ); eye damage; and severe central nervous system manifestations, including microcephaly or hydranencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. However, the characteristic triad occurs in less than one-third of cases and a high index of suspicion is necessary to make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In utero congenital HSV infection may also occur by ascending infection, usually after prolonged rupture of membranes in mothers with active HSV infection near the time of delivery. Ascending transplacental infection of the fetus through intact amniotic membranes may also occur, and neonatal herpes simplex virus infection has been documented after cesarean section in mothers with intact amniotic membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The clinical presentation of newborns with intrauterine HSV acquired by ascending infection may be mild, with only cutaneous skin lesions or cutaneous scarring present, to severe, with signs and symptoms of disseminated HSV disease and fatal neonatal pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neonatal HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal HSV may be classified into three main categories for therapeutic and prognostic considerations: localized skin, eye, and mouth (SEM); central nervous system (CNS) with or without SEM; and disseminated disease, which may involve the CNS and SEM in addition to other organs (",
"    <a class=\"graphic graphic_figure graphicRef67814 \" href=\"mobipreview.htm?3/42/3758\">",
"     figure 1",
"    </a>",
"    ). Both HSV-1 and HSV-2 may cause SEM, CNS, or disseminated disease; however, HSV-2 has been associated with a poorer outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,11,21,22\">",
"     5,11,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H13#H13\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Skin, eye, mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin, eye, and mouth (SEM) disease accounts for approximately 45 percent of neonatal HSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ]. Neonatal HSV SEM disease may appear benign at onset of illness but is associated with a high risk of progression to CNS or disseminated disease if not treated. SEM disease usually presents in the first two weeks of life but may occur at any time during the first six weeks of life (usually in the first month) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localized skin disease is associated with coalescing or clustering vesicular lesions with an erythematous base (",
"    <a class=\"graphic graphic_picture graphicRef75059 \" href=\"mobipreview.htm?4/3/4159\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. Vesicles may begin or cluster at the presenting part of the body, or at sites of localized trauma, such as scalp monitor sites (",
"    <a class=\"graphic graphic_picture graphicRef56041 \" href=\"mobipreview.htm?38/29/39382\">",
"     picture 5",
"    </a>",
"    ). Skin vesicles also may appear late in the course of disseminated disease.",
"   </p>",
"   <p>",
"    HSV infection of the eye may initially appear asymptomatic. In the neonate, early signs include excessive watering of the eye, crying from apparent eye pain, and conjunctival erythema (",
"    <a class=\"graphic graphic_picture graphicRef78598 \" href=\"mobipreview.htm?27/44/28367\">",
"     picture 6",
"    </a>",
"    ). Periorbital skin vesicles may or may not be present at the time of presentation. HSV keratoconjunctivitis may progress to cataracts and chorioretinitis and result in permanent vision impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,13\">",
"     5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV infection of the oropharynx may initially be asymptomatic, but also may be characterized by localized ulcerative lesions of the mouth, palate, and tongue.",
"   </p>",
"   <p>",
"    Neonates with evidence of SEM disease should undergo a thorough evaluation for CNS and disseminated disease (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Laboratory evaluation'",
"    </a>",
"    below). If SEM disease is treated early, before CNS or disseminated disease occurs, the outcome is favorable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H13#H13\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     CNS disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of neonatal HSV disease involves the CNS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ]. It may occur as a result of localized retrograde spread from the nasopharynx and olfactory nerves to the brain or through hematogenous spread in neonates with disseminated disease. Neonatal HSV CNS disease (also called neonatal HSV meningoencephalitis) usually presents in the second or third week of life, but may occur at any time during the first six weeks of life (usually in the first month) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/23\">",
"     23",
"    </a>",
"    ]. CNS disease may occur with or without SEM involvement and with or without disseminated disease. Between 60 and 70 percent of neonates with HSV CNS disease have skin vesicles at some point during the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of neonatal HSV CNS disease include seizures (focal or generalized), lethargy, irritability, tremors, poor feeding, temperature instability, and full anterior fontanel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ]. Early in the course of HSV CNS disease, none of these signs or symptoms may be apparent.",
"   </p>",
"   <p>",
"    Cerebrospinal fluid (CSF) may be normal early in the course of the illness but classically will show a mononuclear cell pleocytosis, normal or moderately low glucose concentration, and mildly elevated protein. Abnormalities of the CSF may be more pronounced as CNS disease progresses. Red blood cells are not significantly associated with neonatal HSV CNS disease and are more likely to be caused by an apparent \"bloody tap\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The electroencephalogram (EEG) often is abnormal very early in the course of CNS disease and may show focal or multifocal periodic epileptiform discharges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,26\">",
"     5,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Electroencephalogram'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Computed tomography (CT) and magnetic resonance (MR) imaging of the brain may be normal early in the course of CNS disease. Several days to a week into illness, neuroimaging studies may show parenchymal brain edema or attenuation, hemorrhage, or destructive lesions involving the temporal, frontal, parietal, or brainstem regions of the brain (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64607 \" href=\"mobipreview.htm?9/41/9874\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Diagnostic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of vesicles, the initial presentation of HSV CNS disease may be indistinguishable from other causes of neonatal sepsis or meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Many experts recommend evaluation for HSV CNS disease with HSV DNA PCR and other studies, and empiric treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    in all neonates with aseptic meningitis or other signs and symptoms of meningoencephalitis without an obvious bacterial cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Laboratory evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Acyclovir therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35640?source=see_link&amp;anchor=H12#H12\">",
"     \"Viral meningitis: Management, prognosis, and prevention in children\", section on 'Empiric antivirals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-fourth of neonatal HSV disease is the disseminated form, which involves multiple organs, including the liver, lungs, adrenals, central nervous system, skin, eye, or mouth (",
"    <a class=\"graphic graphic_picture graphicRef61272 \" href=\"mobipreview.htm?43/2/44073\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53519 \" href=\"mobipreview.htm?39/58/40871\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63300 \" href=\"mobipreview.htm?37/8/38024\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52818 \" href=\"mobipreview.htm?13/43/14009\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ]. The central nervous system is involved in 60 to 75 percent of cases of disseminated neonatal HSV, usually through a hematogenously acquired meningoencephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/23\">",
"     23",
"    </a>",
"    ]. Maternal fever is a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/12,22,29-32\">",
"     12,22,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonates with disseminated HSV often present in the first week of life with nonspecific signs and symptoms of neonatal sepsis, including temperature dysregulation (fever or hypothermia), apnea, irritability, lethargy, respiratory distress, abdominal distension, and ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. Rarely, neonates with HSV infection may present with fever alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/33\">",
"     33",
"    </a>",
"    ]. The diagnosis of disseminated neonatal HSV disease often is delayed until the second week of life, awaiting the results of evaluation for bacterial sepsis. As disseminated neonatal HSV progresses, hepatitis with elevated liver transaminases, ascites and direct hyperbilirubinemia, neutropenia, thrombocytopenia, disseminated intravascular coagulation, hemorrhagic pneumonitis with or without effusion, necrotizing enterocolitis, and meningoencephalitis with seizures may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. In advanced disseminated neonatal HSV disease, fever is often absent, and hypothermia, often accompanied by respiratory failure and shock, is more prominent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,32\">",
"     5,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin vesicles may appear late in the course of disseminated HSV disease, but more than 20 percent of neonates with disseminated HSV disease do not have vesicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe, progressive viral pneumonia with respiratory failure, requiring mechanical ventilation or extracorporeal life support, may be caused by HSV in the neonate and young infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute liver failure, often requiring liver transplantation, is another life-threatening disease that may be caused by HSV hepatitis in the neonate and young infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality exceeds 80 percent in untreated disseminated neonatal HSV. Unfortunately, the diagnosis is often made or confirmed at autopsy, after extensive organ damage has occurred (",
"    <a class=\"graphic graphic_picture graphicRef61272 \" href=\"mobipreview.htm?43/2/44073\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53519 \" href=\"mobipreview.htm?39/58/40871\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63300 \" href=\"mobipreview.htm?37/8/38024\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52818 \" href=\"mobipreview.htm?13/43/14009\">",
"     picture 10",
"    </a>",
"    ). Current efforts are focused on identifying high-risk neonates with a sepsis-like picture, meningoencephalitis, progressive pneumonitis, or hepatitis with liver failure, who may be candidates for HSV screening tests (eg, platelet count, liver transaminases, HSV DNA PCR of the blood), and empiric antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/7,12,31,36\">",
"     7,12,31,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of neonatal herpes simplex virus (HSV) includes a number of infectious and noninfectious conditions that are associated with sepsis, central nervous system manifestations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vesicular skin lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial sepsis and meningitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=see_link\">",
"       \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link&amp;anchor=H11#H11\">",
"       \"Group B streptococcal infection in neonates and young infants\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enterovirus, particularly during the enteroviral season [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/10\">",
"       10",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Infections in neonates'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abusive head injury (central nervous system disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/37\">",
"       37",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other neonatal infections, such as cytomegalovirus, toxoplasmosis, syphilis, and rubella (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link\">",
"       \"Overview of TORCH infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Varicella-zoster virus infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"       \"Varicella-zoster infection in the newborn\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral hepatitis (other than HSV), or drug-induced or toxic liver damage",
"     </li>",
"     <li>",
"      Viral pneumonia, such as respiratory syncytial virus or adenovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H13#H13\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Pneumonia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H15#H15\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other conditions that cause vesicles in neonates, such as staphylococcal skin infection and noninfectious diseases, such as incontinentia pigmenti, acrodermatitis enteropathica (",
"      <a class=\"graphic graphic_picture graphicRef71329 \" href=\"mobipreview.htm?39/34/40481\">",
"       picture 11",
"      </a>",
"      ), transient neonatal pustular melanosis, and erythema toxicum (",
"      <a class=\"graphic graphic_picture graphicRef70785 \" href=\"mobipreview.htm?36/53/37713\">",
"       picture 12",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link\">",
"       \"Vesiculobullous and pustular lesions in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link&amp;anchor=H8#H8\">",
"       \"Zinc deficiency and supplementation in children and adolescents\", section on 'Acrodermatitis enteropathica'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=see_link&amp;anchor=H4#H4\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Erythema toxicum neonatorum'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=see_link&amp;anchor=H5#H5\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Transient neonatal pustular melanosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Microbiologic studies (eg, cultures, polymerase chain reaction tests) may help to differentiate neonatal HSV from other infections conditions. Noninfectious dermatologic conditions may have a characteristic clinical course (eg, transient neonatal pustular melanosis, incontinentia pigmenti). However, given increased morbidity and mortality of neonatal HSV disease, empiric therapy for HSV may be warranted (after appropriate microbiologic specimens are obtained) pending definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Acyclovir therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal herpes simplex virus (HSV) infection is clinically challenging. Early manifestations may be subtle and nonspecific. Prompt treatment requires early consideration of neonatal HSV as a possibility in neonates with mucocutaneous lesions, central nervous system abnormalities, or a sepsis-like picture.",
"   </p>",
"   <p>",
"    The laboratory diagnosis of neonatal HSV infection may be established through isolation of HSV in traditional monolayer cell culture or enhanced cell culture systems, detection of viral DNA using polymerase chain reaction (PCR) assays, and detection of viral antigens using rapid direct immunofluorescence assays (DFA) or enzyme immunoassays (EIA). Negative HSV cultures, PCR, and rapid tests do",
"    <strong>",
"     not",
"    </strong>",
"    exclude neonatal HSV, and the accuracy of EIA tests to diagnose neonatal HSV infection is unknown. Serology is generally not helpful in the diagnosis of neonatal HSV at the time of presentation.",
"   </p>",
"   <p>",
"    Electroencephalography (EEG) should be performed in all neonates suspected to have CNS involvement. In addition, neuroimaging with enhanced computerized tomography (CT) or magnetic resonance imaging (MR) is recommended to determine the location and extent of brain involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Electroencephalogram'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Diagnostic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal herpes simplex virus (HSV) infection should be suspected in neonates and infants up to six weeks of age with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucocutaneous vesicles",
"     </li>",
"     <li>",
"      Sepsis-like illness (fever or hypothermia, irritability, lethargy, respiratory distress, apnea, abdominal distension, ascites)",
"     </li>",
"     <li>",
"      CSF pleocytosis",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal neurologic signs",
"     </li>",
"     <li>",
"      Abnormal neuroimaging",
"     </li>",
"     <li>",
"      Respiratory distress, apnea, or progressive pneumonitis",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Elevated liver transaminases, viral hepatitis, or acute liver failure",
"     </li>",
"     <li>",
"      Conjunctivitis, excessive tearing, or painful eye symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early in the clinical course, some neonates with HSV infection may present with persistent fever and negative bacterial cultures.",
"   </p>",
"   <p>",
"    Neonatal HSV infection remains a possibility in infants born to women who received suppressive therapy during pregnancy. Although suppressive therapy markedly reduces the risk of asymptomatic shedding, it does not completely eliminate it. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H28#H28\">",
"     \"Genital herpes simplex virus infection and pregnancy\", section on 'Suppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive laboratory evaluation for HSV should be performed in all neonates with suspected or proven HSV disease. Comprehensive evaluation is necessary, even in infants who appear to have isolated skin, eye, and mouth (SEM) disease because clinical and laboratory abnormalities may be absent early in the course of central nervous system (CNS) and disseminated disease. The comprehensive laboratory evaluation includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,12,23,36\">",
"     5,12,23,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count, including differential and platelet count",
"     </li>",
"     <li>",
"      Liver transaminases, total and direct bilirubin, ammonia (ammonia should be performed to exclude liver failure and metabolic disease in neonates with elevated liver enzymes and fulminant sepsis, but is not necessary for all neonates with suspected HSV)",
"     </li>",
"     <li>",
"      Blood urea nitrogen (BUN), creatinine, and urinalysis (to assess renal function and hydration status)",
"     </li>",
"     <li>",
"      HSV DNA PCR of the blood",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) cell count, glucose, protein, and HSV DNA PCR",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Swabs/scrapings",
"      </span>",
"      of skin or mucous membrane lesions for HSV direct immunofluorescence assay (DFA) and viral culture",
"     </li>",
"     <li>",
"      Surface cultures from the conjunctivae, mouth, nasopharynx, and rectum (some experts suggest swab specimens from the conjunctivae, mouth, nasopharynx, and rectum can be obtained with a single swab&mdash;starting with eyes and ending with the rectum&mdash;and placed in one viral transport media tube, or collected with multiple swabs, which are then placed in a single viral transport media tube); positive cultures from these sites that are obtained &gt;12 to 24 hours after birth indicate viral replication and are suggestive of infection, rather than contamination from intrapartum exposure",
"     </li>",
"     <li>",
"      Viral cultures of other specimens as indicated (eg, duodenal aspirate, ascites fluid, tracheal aspirate)",
"     </li>",
"     <li>",
"      Evaluation for bacterial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metabolic disease as indicated by the clinical scenario (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=see_link\">",
"       \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of HSV by viral cell culture is the definitive laboratory method of establishing the presence of an active HSV infection in the neonate. Isolation of HSV from surface sites of the neonate, such as skin lesions, eye or conjunctivae, mouth or oropharyngeal secretions, and stool or rectum, is always a significant finding and is the most common and noninvasive method to obtain evidence of active infection with HSV, particularly if obtained 12 to 24 hours after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,23\">",
"     5,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonates with disseminated disease may have HSV isolated from their blood. Neonates with HSV hepatitis or necrotizing enterocolitis may have HSV isolated from duodenal aspirates, ascites fluid, or liver tissue. HSV may be isolated from tracheal aspirates in neonates with HSV pneumonia, and isolation of HSV from the CSF or brain tissue is diagnostic of CNS involvement.",
"   </p>",
"   <p>",
"    HSV is a relatively hearty virus and grows readily on most cell lines used in clinical diagnostic virology laboratories. Evidence of viral cytopathic effect (",
"    <a class=\"graphic graphic_picture graphicRef81175 \" href=\"mobipreview.htm?36/45/37586\">",
"     picture 1",
"    </a>",
"    ) is usually evident under light microscopy in one to three days. Fresh vesicular lesions of the skin often are positive within 24 hours of incubation, whereas isolation from CSF or other sites may require several days. Viral cultures that remain negative at 10 days usually remain negative. HSV isolated in cell culture can be quickly and reliably typed as HSV-1 or HSV-2 using commercially available type-specific immunofluorescence assay reagents.",
"   </p>",
"   <p>",
"    Twenty-four-hour cell culture enhancement systems, such as shell vial centrifugation fluorescent foci cultures (SVC) and enzyme-linked virus inducible systems (ELVIS), are used in many clinical laboratories and provide rapid detection of HSV in clinical systems within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The performance of these systems is generally comparable to cell culture in detecting HSV in skin and mucous membrane lesions, but not all these assays are able to distinguish and type HSV-1 or HSV-2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     PCR testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6571242\">",
"    <span class=\"h4\">",
"     CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of HSV DNA in the CSF of a neonate confirms the diagnosis of central nervous system (CNS) involvement. CSF HSV PCR is more sensitive than viral culture in most cases. However, presence of blood or high protein in the CSF may interfere with some PCR assays and produce false negative results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/40-45\">",
"     40-45",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In neonates with evidence of CNS involvement, such as seizures, focal neurologic signs, abnormal CSF, or abnormal brain imaging, the detection of HSV DNA confirms the diagnosis of HSV meningoencephalitis. However, neonates also may have HSV infection of the CNS without overt clinical, laboratory, or imaging signs of meningoencephalitis. Approximately 25 percent of neonates with HSV apparently localized to the skin, eye, or mouth, and more than 90 percent of neonates with disseminated HSV disease, may have HSV DNA detected in their CSF by PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, it is imperative to include a CSF examination and CSF HSV PCR in all neonates with suspected or proven neonatal HSV infection.",
"    <br/>",
"    <br/>",
"    Negative CSF HSV PCR does not exclude the diagnosis of HSV CNS disease. Apparent false negative CSF HSV PCR results may be obtained in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,40,42,45\">",
"     5,40,42,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonates with CNS involvement early in the course of illness",
"     </li>",
"     <li>",
"      CSF samples obtained several days into antiviral therapy",
"     </li>",
"     <li>",
"      CSF samples that contain red blood cells or high levels of protein",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CSF HSV PCR should be repeated during the first week of illness if neonatal HSV CNS disease is strongly suspected and the initial CSF PCR was negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/46\">",
"     46",
"    </a>",
"    ]. CSF HSV DNA also may persist despite intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy and may be a risk factor for poor neurodevelopmental outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H13#H13\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6571346\">",
"    <span class=\"h4\">",
"     Blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates with severe sepsis syndrome associated with disseminated intravascular coagulation, hepatitis, or thrombocytopenia, the presence of HSV DNA in the blood or plasma confirms the diagnosis of disseminated neonatal HSV disease and provides the opportunity for early initiation of antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,12,36,44,47\">",
"     5,12,36,44,47",
"    </a>",
"    ]. Most neonates with disseminated neonatal HSV disease will have negative bacterial cultures of the blood. However, bacterial coinfections can occur, especially in neonates with liver and intestinal involvement, where gram-negative bacteremia and sepsis may compound the clinical presentation of neonatal HSV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6571353\">",
"    <span class=\"h4\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of HSV DNA in amniotic fluid is diagnostic of in utero or congenital HSV. Detection of HSV DNA in other tissues or bodily fluids (eg, ascites, tracheal aspirate) provides evidence of HSV disease in the neonate. Detection of HSV DNA in the eye or conjunctivae may help establish the diagnosis of neonatal blepharoconjunctivitis or keratitis due to HSV, particularly in neonates in whom pretreatment with antiviral ophthalmic drops or systemic therapy may influence the viral culture results.",
"   </p>",
"   <p>",
"    HSV DNA PCR on skin or mucous membrane lesions is generally",
"    <strong>",
"     not",
"    </strong>",
"    recommended, since viral culture provides the diagnosis in a rapid and timely manner, and the high titer of virus in skin and mucous membrane lesions may cause cross-contamination in the PCR laboratory. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Viral culture'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     DFA and EIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence assays (DFA) and enzyme immunoassays (EIA) methods permit rapid detection of HSV antigens in skin and mucous membrane lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/39,48\">",
"     39,48",
"    </a>",
"    ]. DFA has high specificity for HSV infection, and typing of the HSV antigens may be done directly on material on the slide. However, DFA is not as sensitive as culture in many patients, and accuracy depends on obtaining an adequate specimen containing cells from scrapings of the base of mucocutaneous lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EIA is primarily used to screen asymptomatic or pregnant women for HSV genital infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/48\">",
"     48",
"    </a>",
"    ]. Both false positive and false negative results may occur, and combination with cell culture is recommended to optimize accuracy. The performance of rapid EIA in the diagnosis of neonatal HSV infection is not well established, highlighting the need for cell culture to confirm the diagnosis of HSV in neonates. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Viral culture'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests generally are not helpful in the diagnosis of neonatal HSV infection but may be used to identify HSV-2 infection in pregnant women so that steps can be taken to prevent neonatal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography (EEG) should be performed in all neonates suspected to have CNS involvement, particularly those with seizures, abnormal movements suspicious for seizures, or abnormal cerebrospinal fluid (CSF).",
"   </p>",
"   <p>",
"    EEG is highly sensitive for neonatal HSV infection with CNS involvement and often is abnormal before CT or MR imaging. An abnormal EEG with periodic or quasiperiodic epileptiform discharges, especially if they are focal or multifocal, is characteristic of neonatal HSV meningoencephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Brain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging with enhanced computerized tomography (CT) or magnetic resonance imaging (MR) is recommended to determine the location and extent of brain involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. MR imaging is preferred because it has been shown to be more sensitive than CT in older patients, but CT is acceptable if MR imaging cannot be readily performed. Prenatal ultrasound may show fetal brain damage in intrauterine HSV disease, but neonatal ultrasound often underrepresents the extent of brain involvement and should not be used as the sole imaging study.",
"   </p>",
"   <p>",
"    The imaging findings of neonatal HSV CNS disease are variable. Neuroimaging may be normal early in the course of CNS disease. Several days to a week into illness, neuroimaging studies may show parenchymal brain edema or attenuation, hemorrhage, or destructive lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. In addition to the classic temporal lobe destructive lesions, imaging abnormalities may be multifocal or limited to the brainstem or cerebellum (",
"    <a class=\"graphic graphic_picture graphicRef78598 \" href=\"mobipreview.htm?27/44/28367\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because neuroimaging may be normal early in the course, negative imaging with CT or conventional MR imaging does not exclude HSV CNS involvement. Diffusion-weighed imaging, which may show evidence of restricted diffusion, is an important adjunct to MR imaging in neonates suspected of having CNS involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/31/35321/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs may demonstrate bilateral, diffuse pneumonitis in neonates with primary HSV pneumonia or in infants with disseminated HSV disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Abdominal ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal ultrasonography in neonates with HSV hepatitis and acute liver failure may demonstrate ascites and enlarged liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/34/3618?source=see_link\">",
"       \"Patient information: Newborn conjunctivitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal herpes simplex virus (HSV) infection occurs in approximately 1 in 3200 to 10,000 live births. Neonatal HSV may be acquired in utero (congenital HSV), perinatally (approximately 85 percent of cases), or postnatally (approximately 10 percent of cases). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrauterine HSV is associated with hydrops fetalis and fetal in utero demise. Survivors may exhibit a characteristic triad of skin vesicles or scarring, eye damage, and severe central nervous system manifestations, including microcephaly or hydranencephaly. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intrauterine HSV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal HSV may be classified into three main categories for therapeutic and prognostic considerations: localized skin, eye, and mouth (SEM); central nervous system (CNS) with or without SEM; and disseminated disease involving multiple organs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neonatal HSV'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H13#H13\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized SEM disease is characterized by coalescing or clustering vesicular lesions of the skin (",
"      <a class=\"graphic graphic_picture graphicRef75059 \" href=\"mobipreview.htm?4/3/4159\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef56041 \" href=\"mobipreview.htm?38/29/39382\">",
"       picture 5",
"      </a>",
"      ); excessive tearing, eye pain, conjunctival edema;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      localized ulcerative lesions of the mouth, palate, and tongue. Neonates with evidence of SEM disease should undergo a thorough evaluation for CNS and disseminated disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Skin, eye, mouth'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of neonatal HSV CNS disease include seizures (focal or generalized), lethargy, irritability, tremors, poor feeding, temperature instability (fever or hypothermia), and full anterior fontanel. Electroencephalography often is abnormal early in the course of CNS disease when cerebrospinal fluid and neuroimaging studies may be normal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'CNS disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated neonatal HSV disease involves multiple organs. Neonates with disseminated HSV often present in the first week of life with nonspecific signs and symptoms of neonatal sepsis (eg, temperature dysregulation, apnea, irritability, lethargy, respiratory distress, abdominal distension, ascites). The mortality of untreated disseminated neonatal HSV exceeds 80 percent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of neonatal HSV includes a number of infectious and noninfectious conditions that are associated with sepsis, central nervous system manifestations, pneumonitis, hepatitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vesicular skin lesions. Pending definitive diagnosis, empiric therapy for neonatal HSV may be warranted (after appropriate microbiologic specimens are obtained). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H4#H4\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Acyclovir therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonatal HSV infection should be suspected in neonates with lesions of the skin, eyes, or mouth; CNS abnormality (CSF pleocytosis, seizures, focal neurologic signs, abnormal neuroimaging); or sepsis-like illness (respiratory distress, apnea, abdominal distension, ascites, progressive pneumonitis, temperature dysregulation, hepatitis, thrombocytopenia). Early in the clinical course, some neonates with HSV infection may present with persistent fever and negative bacterial cultures. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical suspicion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of neonatal HSV infection may be established through isolation of HSV in culture, detection of HSV DNA using polymerase chain reaction (PCR) assays, and detection of HSV antigens using rapid direct immunofluorescence assays or enzyme immunoassays. Negative HSV cultures, PCR, and rapid tests do",
"      <strong>",
"       not",
"      </strong>",
"      exclude neonatal HSV. Electroencephalography and neuroimaging should be performed in all neonates with suspected HSV-associated CNS involvement. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/1\">",
"      Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/2\">",
"      Flagg EW, Weinstock H. Incidence of neonatal herpes simplex virus infections in the United States, 2006. Pediatrics 2011; 127:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/3\">",
"      Roberts S. Herpes simplex virus: incidence of neonatal herpes simplex virus, maternal screening, management during pregnancy, and HIV. Curr Opin Obstet Gynecol 2009; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/4\">",
"      Mahnert N, Roberts SW, Laibl VR, et al. The incidence of neonatal herpes infection. Am J Obstet Gynecol 2007; 196:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/5\">",
"      Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/6\">",
"      Caviness AC, Demmler GJ, Swint JM, Cantor SB. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates. Arch Pediatr Adolesc Med 2008; 162:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/7\">",
"      Davis KL, Shah SS, Frank G, Eppes SC. Why are young infants tested for herpes simplex virus? Pediatr Emerg Care 2008; 24:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/8\">",
"      Ambroggio L, Lorch SA, Mohamad Z, et al. Congenital anomalies and resource utilization in neonates infected with herpes simplex virus. Sex Transm Dis 2009; 36:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/9\">",
"      Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol 2007; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/10\">",
"      Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/11\">",
"      Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009; 361:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/12\">",
"      Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. Pediatr Infect Dis J 2008; 27:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/13\">",
"      Malik AN, Hildebrand GD, Sekhri R, Russell-Eggitt IM. Bilateral macular scars following intrauterine herpes simplex virus type 2 infection. J AAPOS 2008; 12:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/14\">",
"      Koch LH, Fisher RG, Chen C, et al. Congenital herpes simplex virus infection: two unique cutaneous presentations associated with probable intrauterine transmission. J Am Acad Dermatol 2009; 60:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/15\">",
"      Vasileiadis GT, Roukema HW, Romano W, et al. Intrauterine herpes simplex infection. Am J Perinatol 2003; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/16\">",
"      Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. Pediatr Infect Dis J 2011; 30:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/17\">",
"      Hyde SR, Giacoia GP. Congenital herpes infection: placental and umbilical cord findings. Obstet Gynecol 1993; 81:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/18\">",
"      Peng J, Krause PJ, Kresch M. Neonatal herpes simplex virus infection after cesarean section with intact amniotic membranes. J Perinatol 1996; 16:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/19\">",
"      Andersen RD. Herpes simplex virus infection of the neonatal respiratory tract. Am J Dis Child 1987; 141:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/20\">",
"      Mascola L, Cable DC, Walsh P, Guinan ME. Neonatal herpes simplex virus death manifested as rapidly progressive pneumonia. Clin Pediatr (Phila) 1984; 23:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/21\">",
"      Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/22\">",
"      Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:450.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Herpes simplex. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/24\">",
"      Toth C, Harder S, Yager J. Neonatal herpes encephalitis: a case series and review of clinical presentation. Can J Neurol Sci 2003; 30:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/25\">",
"      Corey L, Whitley RJ, Stone EF, Mohan K. Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. Lancet 1988; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/26\">",
"      Mizrahi EM, Tharp BR. A characteristic EEG pattern in neonatal herpes simplex encephalitis. Neurology 1982; 32:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/27\">",
"      Long SS. In defense of empiric acyclovir therapy in certain neonates. J Pediatr 2008; 153:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/28\">",
"      Kimberlin DW. When should you initiate acyclovir therapy in a neonate? J Pediatr 2008; 153:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/29\">",
"      O'Riordan DP, Golden WC, Aucott SW. Herpes simplex virus infections in preterm infants. Pediatrics 2006; 118:e1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/30\">",
"      Stanberry LR. Neonatal herpes in premature infants: a special problem. Pediatrics 2006; 118:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/31\">",
"      Fidler KJ, Pierce CM, Cubitt WD, et al. Could neonatal disseminated herpes simplex virus infections be treated earlier? J Infect 2004; 49:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/32\">",
"      Knezevic A, Martic J, Stanojevic M, et al. Disseminated neonatal herpes caused by herpes simplex virus types 1 and 2. Emerg Infect Dis 2007; 13:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/33\">",
"      Filippine MM, Katz BZ. Neonatal herpes simplex virus infection presenting with fever alone. J Hum Virol 2001; 4:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/34\">",
"      Meyer TA, Warner BW. Extracorporeal life support for the treatment of viral pneumonia: collective experience from the ELSO registry. Extracorporeal Life Support Organization. J Pediatr Surg 1997; 32:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/35\">",
"      Riediger C, Sauer P, Matevossian E, et al. Herpes simplex virus sepsis and acute liver failure. Clin Transplant 2009; 23 Suppl 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/36\">",
"      Cantey JB, Mej&iacute;as A, Wallihan R, et al. Use of blood polymerase chain reaction testing for diagnosis of herpes simplex virus infection. J Pediatr 2012; 161:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/37\">",
"      Kurtz J, Anslow P. Infantile herpes simplex encephalitis: diagnostic features and differentiation from non-accidental injury. J Infect 2003; 46:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/38\">",
"      LaRocco MT. Evaluation of an enzyme-linked viral inducible system for the rapid detection of Herpes simplex virus. Eur J Clin Microbiol Infect Dis 2000; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/39\">",
"      Verano L, Michalski FJ. Comparison of a direct antigen enzyme immunoassay, Herpchek, with cell culture for detection of herpes simplex virus from clinical specimens. J Clin Microbiol 1995; 33:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/40\">",
"      Espy MJ, Uhl JR, Mitchell PS, et al. Diagnosis of herpes simplex virus infections in the clinical laboratory by LightCycler PCR. J Clin Microbiol 2000; 38:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/41\">",
"      Slomka MJ, Emery L, Munday PE, et al. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998; 55:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/42\">",
"      Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1996; 174:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/43\">",
"      Malm G, Forsgren M. Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum. Arch Dis Child Fetal Neonatal Ed 1999; 81:F24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/44\">",
"      Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991; 164:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/45\">",
"      Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr 1993; 123:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/46\">",
"      Frenkel LM. Challenges in the diagnosis and management of neonatal herpes simplex virus encephalitis. Pediatrics 2005; 115:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/47\">",
"      Mej&iacute;as A, Bustos R, Ardura MI, et al. Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. J Perinatol 2009; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/31/35321/abstract/48\">",
"      Reina J, Saurina J, Fernandez-Baca V, et al. Evaluation of a direct immunofluorescence cytospin assay for the detection of herpes simplex virus in clinical samples. Eur J Clin Microbiol Infect Dis 1997; 16:851.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6037 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35321=[""].join("\n");
var outline_f34_31_35321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intrauterine HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neonatal HSV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Skin, eye, mouth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - CNS disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Viral culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - PCR testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6571242\">",
"      CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6571346\">",
"      Blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6571353\">",
"      Other sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - DFA and EIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Brain imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Abdominal ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6037|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/41/9874\" title=\"diagnostic image 1\">",
"      Neonatal HSV brain CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6037|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/42/3758\" title=\"figure 1\">",
"      Neonatal HSV SSx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6037|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/45/37586\" title=\"picture 1\">",
"      Herpes virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/27/44471\" title=\"picture 2\">",
"      HSV cytopathic effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/28/6597\" title=\"picture 3\">",
"      Intrauterine HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4159\" title=\"picture 4\">",
"      Neonatal HSV neck vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/29/39382\" title=\"picture 5\">",
"      Neonatal HSV scalp vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/44/28367\" title=\"picture 6\">",
"      Neonatal HSV eye vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/2/44073\" title=\"picture 7\">",
"      Disseminated neonatal HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/58/40871\" title=\"picture 8\">",
"      Neonatal HSV liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/8/38024\" title=\"picture 9\">",
"      Neonatal HSV lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/43/14009\" title=\"picture 10\">",
"      Neonatal HSV adrenals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/34/40481\" title=\"picture 11\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/53/37713\" title=\"picture 12\">",
"      Erythema toxicum face",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/34/3618?source=related_link\">",
"      Patient information: Newborn conjunctivitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35640?source=related_link\">",
"      Viral meningitis: Management, prognosis, and prevention in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_31_35322="Altered prescriptions";
var content_f34_31_35322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Altered prescriptions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 745px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35322=[""].join("\n");
var outline_f34_31_35322=null;
var title_f34_31_35323="Aircraft cabin pressurization";
var content_f34_31_35323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cabin pressurization in different commercial aircraft",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Aircraft type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Differential pressure, psi",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cabin altitude, ft",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-727",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        5400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-757",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        5400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-767",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        5400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-747",
"       </td>",
"       <td>",
"        8.9",
"       </td>",
"       <td>",
"        4700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-737",
"       </td>",
"       <td>",
"        7.45",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DC-9",
"       </td>",
"       <td>",
"        7.76",
"       </td>",
"       <td>",
"        7300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A-300",
"       </td>",
"       <td>",
"        8.25",
"       </td>",
"       <td>",
"        6100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A-320",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L-1011",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        5800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BAC-111",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        7900",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cottrell JJ, Chest 1988; 98:81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35323=[""].join("\n");
var outline_f34_31_35323=null;
var title_f34_31_35324="Observed signs of catatonia";
var content_f34_31_35324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F53391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F53391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Observed signs of catatonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description and examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immobility",
"       </td>",
"       <td>",
"        Hypokinetic or akinetic behavior that is not influenced by external stimuli.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stupor",
"       </td>",
"       <td>",
"        Decreased alertness, hypoactivity, and diminished responses to voice and painful stimuli.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excitement",
"       </td>",
"       <td>",
"        Impulsive, frantic, and stereotypic behavior that may include sudden outbursts of talking, singing, dancing, and tearing of clothes. Patients may be irritable and damage objects or injure themselves or others. Excitement may suddenly alternate with stupor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutism",
"       </td>",
"       <td>",
"        Patients are awake but verbally unresponsive. Mutism is not always associated with immobility and may appear elective. Less severe forms of mutism include lack of spontaneous speech, sluggish responses to questions with automatic answers such as \"I don't know\" (speech-prompt), and speaking with progressively less volume until speech is an inaudible mumble (prosectic speech).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posturing (catalepsy)",
"       </td>",
"       <td>",
"        Voluntarily maintaining a position of the body or a body part for a long time; eg, standing or lying down in the same position, an exaggerated pucker, lying in bed with the head elevated and unsupported as if on a pillow, holding arms above the head or raised in a prayer-like manner, and holding fingers and hands in odd positions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echophenomena",
"       </td>",
"       <td>",
"        Echolalia (senseless repetition of another person's utterances) and echopraxia (senseless repetition of another person's movements).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Speech mannerisms",
"       </td>",
"       <td>",
"        Robotic speech, feigned foreign accent, palilalia or verbigeration (involuntary repetition of words or phrases).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral mannerisms",
"       </td>",
"       <td>",
"        Odd, purposeful movements, such as holding hands as if they were handguns or saluting passersby, or exaggerated or stilted caricatures of mundane movements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stereotypy",
"       </td>",
"       <td>",
"        Non-goal-directed, repetitive movements that often are awkward or stiff; examples include grimacing, teeth/tongue clicking, rocking, sniffing, biting, or automatically touching or tapping.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staring",
"       </td>",
"       <td>",
"        Fixed gaze with little or no scanning of the environment and decreased blinking.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Fink M, Taylor MA. The catatonia syndrome: Forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.",
"       </li>",
"       <li>",
"        American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.",
"       </li>",
"       <li>",
"        Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129.",
"       </li>",
"       <li>",
"        Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005; 9:1.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35324=[""].join("\n");
var outline_f34_31_35324=null;
var title_f34_31_35325="Flow volume loops in airway obstruction";
var content_f34_31_35325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Flow-volume loops in upper airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 151px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel shows fixed upper airway obstruction with flow limitation and flattening of both the inspiratory and expiratory limbs of the flow-volume loop. Middle panel shows dynamic (or variable, nonfixed) extrathoracic obstruction with flow limitation and flattening of the inspiratory limb of the loop. Right panel shows dynamic (or variable, nonfixed) intrathoracic obstruction with flow limitation and flattening of the expiratory limb of the loop.",
"    <div class=\"footnotes\">",
"     TLC: total lung capacity; RV: residual volume.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Stoller JK, Cleve Clin J Med 1992; 59:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35325=[""].join("\n");
var outline_f34_31_35325=null;
var title_f34_31_35326="Benefit of ACE inhibitors in acute MI";
var content_f34_31_35326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Benefit of ACE inhibitors in all patients with acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reduction in deaths with the use of lisinopril or captopril (red and green bars) versus control (blue solid bars) after acute myocardial infarction in the GISSI-3 and ISIS-4 trials. The numbers in parentheses refer to the portion of mortality reduction attributable to the ACE inhibitor for each of the three time periods shown; approximately 30 percent of the total mortality reduction occurred within the first 24 hours following symptom onset, supporting the early use of these agents in acute myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Latini R, Maggioni AP, Flather M, et al. Circulation 1995; 92:3132.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35326=[""].join("\n");
var outline_f34_31_35326=null;
var title_f34_31_35327="Tracheal stenosis in GPA";
var content_f34_31_35327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal stenosis in granulomatosis with polyangiitis (Wegener's)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conventional tomogram shows moderate cervical tracheal stenosis due to granulomatosis with polyangiitis (Wegener's).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_31_35327=[""].join("\n");
var outline_f34_31_35327=null;
